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ABSTRACT 
  
Research Objective 
While the adoption of e-prescribing is growing, the Institute of Medicine’s recommendations that 
all prescriptions be routed electronically by 2010 certainly has not been met. Therefore, the 
objective of this study is to compare the factors that physicians find encouraging and 
discouraging about e-prescribing based on their e-prescribing adoption status. 
Study Design 
Cross-sectional, descriptive design. An Internet-based survey was sent to national convenience 
sample of physicians. Using e-prescribing literature, 44 items were developed concerning 
various factors related to the adoption of e-prescribing. Physicians rated how much the factors 
encouraged them or discouraged them about e-prescribing. Analysis procedures included 
descriptive statistics, exploratory factor analysis, reliability analysis, and MANOVA. 
 Results 
The national convenience sample of physicians was obtained from a physician panel. The sample 
consisted of 443 complete responses of primary care physicians (PCPs) in the areas of family 
and general medicine (53.5%), internal medicine (39.5%) and others (7%) currently practicing in 
the United States. Physicians were 51 years old on average. 77.4% of respondents were male, 
70.2% owned a private practice, and 83.7% practiced in rural areas. Exploratory factor analysis 
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procedures resulted in seven components: Pre-implementation factors, technology factors, 
features, external influences, patient factors, post-implementation factors, and cost factors. 
Cronbach’s alpha of the scales ranged from .84 to .95. Overall, respondents reported pre-
implementation factors and cost factors to be slightly discouraging.  Respondents reported 
technology factors, software features, and patient factors to be encouraging, with software 
features being the most encouraging. External influences and post-implementation factors were 
slightly encouraging or discouraging, depending on the group of respondents. 
Conclusions  
Results of this analysis suggest that those respondents who have considered e-prescribing but 
have no intention to adopt it and those respondents who are in the process of adopting e-
prescribing in the next six months are significantly more discouraged about e-prescribing factors 
than those who have adopted e-prescribing greater than six months ago. Interestingly, all 
respondents found electronic prescribing features to be encouraging, and, in fact, the most 
encouraging of all the factors. This may suggest that electronic prescribing vendors are meeting 
the needs of prescribers when it comes to software features.  
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I. INTRODUCTION 
 
The Institute of Medicine (IOM) estimates that “there are at least 1.5 million preventable 
adverse drug events that occur in the United States each year,” and notes that this may actually 
be an underestimate (IOM Report Brief, 2006, p. 1).
  
Many of these errors are preventable and 
occur due to miscommunication between the prescriber and pharmacist as a result of “illegible 
handwriting, unclear abbreviations and dose designations, unclear telephone or verbal orders,” 
and other related problems (eHealth Initiatives Report, 2008, p. 16).  Therefore, the IOM 
recommends that by 2010 “all prescribers and pharmacies be using e-prescriptions” (eHealth 
Initiatives Report, 2008, IOM Report Brief, 2006, p. 3).  
The electronic prescribing (e-prescribing) final rule issued by the Centers for Medicare 
and Medicaid Services (CMS) defines e-prescribing  as “…the transmission, using electronic 
media, of prescription or prescription-related information, between a prescriber, dispenser, 
pharmacy benefits manager (PBM), or health plan, either directly or through an intermediary, 
including an e-prescribing network.  E-prescribing includes, but is not limited to, two-way 
transmissions between the point of care and the dispenser” (Federal Register, 2005). 
The impetus of e-prescribing is the reduction of preventable medication errors by 
generating a legible prescription checked by e-prescribing software for drug-drug and other 
interactions.  According to a national progress report by Surescripts, the electronic routing of 
prescriptions grew from 68 million in 2008 to 191 million in 2009.  The total number of 
prescribers routing prescriptions electronically also grew from 74,000 at the end of 2008 to over
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156,000 by the end of 2009, which is around 25 percent of all office-based prescribers 
(Surescripts, 2009).   
While the adoption of e-prescribing is growing, it may not be growing at a rate that meets 
IOM’s recommendations that all prescriptions be routed electronically by 2010.  Slower than 
desired adoption of e-prescribing is most likely due to the barriers that have been associated with 
both prescribers and pharmacists (Pizzi et al., 2005).
  
Barriers associated with pharmacists are 
becoming less significant as around 85 percent of community pharmacies in the United States are 
connected for electronic prescription routing, and the six largest mail order pharmacies can now 
receive prescriptions electronically (Surescripts, 2009).
 
 Most of the barriers are now associated 
with prescribers and include cost of the system, time to install the system and patient 
confidentiality concerns (Pizzi et al., 2005). 
While demographic factors related to physician adoption of e-prescribing (Kralewski et 
al., 2008; Pizzi et al., 2005), physician beliefs about e-prescribing (Pizzi et al., 2005), and 
general reports of barriers and concerns by physicians have been reported in the literature 
(American Medical Association, 2008; Pizzi et al., 2005), there has been no quantitative 
examination of factors that physicians find encouraging and discouraging about e-prescribing 
and how  those perceptions vary among different types of physicians and their specific state of e-
prescribing.  Discerning the encouraging and discouraging factors that influence physicians is 
important to prioritize initiatives to more adequately facilitate the adoption of e-prescribing.   
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Given this gap in the e-prescribing literature related to physician adoption, the objectives of this 
study are to: 
1. Determine the factors that physicians find encouraging and discouraging   about e-
prescribing. 
2. Compare the factors that physicians find encouraging and discouraging based on their 
specific e-prescribing adoption status. 
3. Determine which demographic factors are significant predictors of physicians’ 
perceptions of factors that are encouraging and discouraging about e-prescribing. 
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II. LITERATURE REVIEW 
 
History and Implementation of Electronic Prescribing 
 In 1992, Walgreens was the first pharmacy to launch an electronic prescribing (e-
prescribing) system, and estimated that they would fill more than 40 million electronic 
prescriptions by 2009 (Walgreens website, 2009).  Then in February 2001, the nation’s three 
largest PBMs (Advance PCS, Express Scripts, and Medco Health Solutions) jointly founded 
RxHub (Surescripts website).  Surescripts was also formed in 2001 by the National Association 
of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) 
(Surescripts website).  RxHub was created as an electronic exchange that would connect 
physicians, pharmacies, pharmacy benefit managers (PBMs), and health plans.  Surescripts 
enabled the two-way electronic communication of prescription information between pharmacists 
and physicians.  RxHub and Surescripts sought to reduce the cost and improve the safety and 
efficiency of the prescription process with the mission of promoting electronic prescribing.   
 With the legalization of e-prescribing in Alaska in August 2007, electronic prescribing 
finally became legal in all 50 states and Washington D.C. (Information Week).  One of the most 
significant developments in e-prescribing was the 2008 merger of Rxhub and Surescripts 
whereby they re-launched themselves as Surescripts (Surescripts website).  As a result of the 
merger of these two organizations, providers will receive “richer” information at the point of 
care because the Surescripts network connects these prescribers to all of the nation’s major chain 
pharmacies (Walgreens, CVS/pharmacy, Wal-Mart, etc.), more than 10,000 independent 
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pharmacies, and to the nation’s leading payers and PBMs (Aetna, CVS Caremark, Express 
Scripts, Medco, etc.) (Surescripts website).    
 Legislation has played an important role in the implementation of e-prescribing.  Most 
recently (on June 1
st
 2010), the Drug Enforcement Agency (DEA) “issued its interim final rule 
allowing for the paperless prescribing of controlled substances” (Drug Store News website).  The 
Medicare Modernization Act of 2003 (MMA) mandated that a system of e-prescribing be 
“established and implemented by 2009 for the electronic transmission of prescription for 
Medicare beneficiaries” (Fink et al., 2006).  In February 2005, the Centers for Medicaid and 
Medicare Services (CMS) issued a proposed rule outlining the standards to be used for e-
prescribing.  In issuing this proposed rule, it accelerated the adoption of e-prescribing to begin in 
January 2006 because of the obvious benefits to safety and quality of prescribing (Fink et al., 
2006).  While it is voluntary for prescribers to use this system outlined by CMS, if they use e-
prescribing for Medicare patients who receive Part D benefits, they must use the standards 
dictated by CMS.  However, these standards are similar to those used by pharmacies for payment 
claims adjudication (Fink et al., 2006). 
 According to MMA provisions, electronic prescribing technology should be capable of  
transmission of formulary information among prescribers, dispensing pharmacies, and
 
Part D 
plans such as: “(1) prescription orders themselves; (2) plan eligibility queries and responses; (3) 
plan benefit information, including
 
the formulary tier and any prior authorization requirement for
 
a given drug; (4) information on drug interactions, other warnings
 
or cautions, and any dosage 
adjustments related to the drug
 
being prescribed or dispensed; (5) appropriate lower-cost 
alternatives,
 if any, for a drug being prescribed; and (6) the patient’s medical history related to a 
covered Part D drug being prescribed
 or dispensed” (Bell & Friedman, 2005). 
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 E-prescribing incentives for Medicare patients were built into the Medicare 
Improvements for Patients and Providers Act (MIPPA) when it was enacted in 2008.  This 
program started in January 2009 and the physicians who successfully adopt e-prescribing by 
2011 will receive annually decreasing incentives until 2013 and those who fail to adopt by 2012 
will be penalized until adoption (Table 1).  Those physicians who rarely write prescriptions will 
be exempt by law for the claim of financial incentives and penalties (Medicare Improvements for 
Patients and Providers Act of 2008). 
Table 1:  Physician Incentive and Penalty Rates by Adoption Year 
 
The Impetus for Electronic Prescribing 
 The most salient impetus for the adoption of electronic prescribing is that hand-written 
prescriptions are more prone to dispensing errors as a result of difficulty in reading and 
interpretation, unclear abbreviations, and unclear verbal communications (eHealth Initiative 
Report, 2008).  This can result in time loss of prescribers and pharmacists for the clarification of 
prescriptions (Schiff & Rucker, 1998), and most importantly, harm to patients.  Therefore, there 
was an immense need to find an alternate way to administer error-free prescriptions.  The nation 
as well as the health care industry is increasingly concerned about patient safety.  This was 
demonstrated in the 1999 Institute of Medicine report “To Err Is Human”, whereby the health 
care industry was encouraged to adopt new technologies to decrease medication errors (Kohn et 
Year 2009 2010 2011 2012 2013 2014 
Incentives 2.0% 2.0% 1.0% 1.0% 0.5% - 
Penalties - - - - 1.0% - 1.5% > - 2.0% 
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al., 1999).  As a result, health care providers have taken a growing interest in e-prescribing to 
improve the prescribing process and reduce errors and costs related to dispensing errors.  Other 
benefits of e-prescribing include easy access to patients’ history and formularies, drug interaction 
alerts, the saving of patients’ time due to electronically sent prescription to pharmacies and easy 
refill requests, records of adverse events, and ability to facilitate post marketing surveillance of 
new drugs and their outcomes (Schiff & Rucker, 1998). 
General Rates of Adoption of Electronic Prescribing  
 It is clear that electronic prescribing helps reduce medication errors, adverse drug events, 
and saves physicians, pharmacists, payers and patients time (Schiff & Rucker, 1998).  However, 
adoption is slow, particularly among physicians (Bell & Friedman, 2005).  Barriers associated 
with pharmacists’ adoption of e-prescribing are becoming less significant as approximately 85 
percent of community pharmacies in the United States are connected for electronic prescription 
routing, and the six largest mail order pharmacies can now receive prescriptions electronically 
(Surescripts, 2009).   
 According to a 2009 national progress report by Surescripts, the electronic routing of 
prescriptions grew from 68 million in 2008 to 191 million in 2009.  The total number of 
prescribers routing prescriptions electronically also grew from 74,000 at the end of 2008 to over 
156,000 by the end of 2009, which is around 25 percent of all office-based prescribers 
(Surescripts, 2009).  Surescripts has identified key factors which have had a great impact on e-
prescribing growth.  First, they attribute growth in e-prescribing to federal and state policies such 
as MIPPA, Health Information Technology for Economic and Clinical Health (HITECH), and 
Certification Commission for Health Information Technology (CCHIT).  Second, they 
acknowledge the increase in education and awareness programs by the government, which has 
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aggressively promoted e-prescribing.  Third, they attribute increased adoption among large 
clinics and health centers to the funding provided by MIPPA.  Finally, some of the initiatives 
taken by payer, PBMs, states, and regions have significantly helped to facilitate the adoption of 
e-prescribing in 2009 (Surescripts, 2009). 
 While the adoption of e-prescribing is growing, it may not be growing at a rate that meets 
IOM’s recommendations that all prescriptions be routed electronically by 2010.  According to 
2004-2005 Community Tracking Study Physician Survey by Pagan et al. (2005), access to IT e-
prescribing is increasing, however only about 3 in 5 prescriptions were written electronically by 
United States physicians.  In a study conducted by Pizzi et al. (2005) only 19% of their study 
population implemented e-prescribing; but, around 52% of physicians were either ready or at 
least thinking about implementing.  
 In light of slow adoption, cited in the literature are various recommendations that may 
help boost adoption of e-prescribing system among physicians.  Those recommendations include 
minimal required data entering with proper flow (Pizzi et al., 2005), limiting pop-up windows to 
only important alerts (Pizzi et al., 2005 and Weingart et al., 2009), and incorporating a font that 
is easier to read (Pizzi et al., 2005).  With proper education and guidance, the Medicare 
Modernization Act (MMA) can also help boost adoption among physicians by providing 
financial incentives for adopters.  An office environment of organizational trust and leadership 
with the involvement and support from staff can help facilitate the implementation of the system 
(Pizzi et al., 2005 and Crosson et al., 2008).  Additionally, physicians should have adequate 
information about a new system’s benefits, limitations and its impact on the workflow of the 
practice.  Technical support provided to physicians and practice staff can also help make the 
implementation process easier (Crosson et al., 2008).  Wang et al. (2009) recommend that more 
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resources should be available to train and educate physicians, that there should be better system 
support, and that there should be system integration to overcome technical and workflow barriers 
related to technology.  
Factors Related to Adoption and Utilization of Electronic Prescribing Among Physicians  
 
 The literature appears inconclusive as to whether adoption and utilization of e-prescribing 
appears to vary accordingly to demographics like age and gender.  Female physicians appear to 
use e-prescribing less; especially in surgical, psychiatry, gynecology or medical groups (Pagan et 
al., 2009).  E-prescribers tend to be younger physicians who have practiced fewer years relative 
to non e-prescribers (Fisher et al., 2007).  Fisher et al. (2007) explain these findings by 
suggesting that older physicians may experience difficulties in changing their prescribing habits 
compared to younger physicians who may be more flexible and comfortable with the technology.  
In contrary, some researchers have found no significant relationships between use of e-
prescribing and physician characteristics like age and gender (Kralewski et al., 2008).   
 There is agreement in the literature that adoption and utilization of e-prescribing vary 
according to practice size.  Pagan et al. (2009) have reported that practices with less than two 
physicians have less access to e-prescribing information technology as well as less actual usage 
of the technology when compared to larger practices like model HMOs.  The findings remain 
consistent with Fisher et al. (2007) and Kralewski et al. (2008), showing that larger practices 
have higher adoption rates compared to smaller practices.  The authors explain these findings by 
suggesting that large practices may have more management capacity (Kralewski et al., 2008) and  
greater access to on-site system support (Fisher et al., 2007)  to help them adopt e-prescribing 
technology more efficiently.   
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 Access to technology in general has been found to be lower among several specialty 
groups like surgical, psychiatry, gynecology or medical specialties (Pagan et al., 2009).  There 
appears to be higher utilization of e-prescribing among primary care physicians (PCPs) such as 
internal medicine, family/general medicine and pediatric physicians (Pagan et al., 2009).  Among 
PCPs, Kralewski et al. (2008) reported higher adoption rates among pediatricians compared to 
internists and family practitioners.  One of the reasons given by Fisher et al. (2007) for higher 
adoption rates among pediatricians is  the lower likelihood of prescribing chronic medication for 
children (Fisher et al., 2007).  The findings were at least partially supported by a study conducted 
by Kralewski et al. (2008) and Pizzi et al. (2005) who found that pediatricians and family 
practitioners report higher e-prescribing usage compared to internists.  Kralewski et al. (2008) 
explain these findings by suggesting that, large practices like multi-specialty practices, which 
may have more family and pediatric physicians, have greater management capacity that can help 
facilitate adoption of e-prescribing more uniformly.   
 Researchers have also explored the association between physicians’ use of electronic 
technology and their computer knowledge and use.  Electronic prescribers are more likely to use 
office computers for billing, patient appointment scheduling, retrieving medical/drug 
information, and communicating with patients via email compared to physicians who do not e-
prescribe (Pizzi et al., 2005).  Physicians who were more comfortable with e-prescribing 
technology wrote more scripts electronically and vice versa.  Similar findings were reported by 
Tan et al. (2009).  However, considering prior experience, no significant association was found 
between prior computer usage and electronic prescribing adoption (Schectman et al., 2005).  
Conflicting findings may be due to inconsistency in the measures used by the researchers to 
approach the same construct.  For instance, Pizzi et al. (2005) captured computer knowledge by 
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asking general technology used within office practice.  Schectman et al. (2005) used computer 
attitude scale to measure computer experience.  Finally, Tan et al. (2009) used self-rating of 
general computer skills.   
 Practice culture variables like organizational trust, emphasis on business approach to 
practice decisions [which means more significance is given to revenue enhancement at highest 
priorities (Kralewski et al., 2005)], and physician autonomy are found to be important for the 
adoption of e-prescribing technology (Kralewski et al., 2008).  The authors recommended that 
instead of physician characteristics, more emphasis should be given to practice culture for 
successful adoption (Kralewski et al., 2008).  The same authors also found that institutions where 
more physicians are involved in decision making also have higher adoption rates (Kralewski et 
al., 2008).   Finally, it is no surprise that financial incentives by payers and the government 
and free product availability to physicians by insurers have been identified as significant reasons 
for adopting e-prescribing (Weingart et al., 2009). 
Experience of Physicians Using Electronic Prescribing  
 Satisfaction with electronic prescribing.  A study conducted in Singapore from 2006-
2007 examined satisfaction among e-prescribers in a primary group setting (Tan et al., 2009).  
Key findings of the study suggest that e-prescribing systems were successfully implemented and 
resulted in satisfaction among the adopters.  Compared to pharmacy staff, most doctors (around 
87%) were more satisfied with e-prescribing system and were less likely to go back to traditional 
prescribing (Tan et al., 2009).   
 In another study, it was found that as time progresses physicians become more 
comfortable with the e-prescribing (Fisher et al., 2007).  In addition, physicians using the e-
prescribing technology for more than 12 months were more satisfied with the system (Pizzi et al., 
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2005 and Fisher et al., 2007), routed more prescriptions electronically, and had fewer follow up 
clarifications with pharmacies compared to physicians who were using the system for less than 
12 months (Pizzi et al., 2005).   
 Value of electronic prescribing.   Focus groups were conducted in Massachusetts to 
examine the value of e-prescribing core components (drug allergy and interaction alerts) and the 
common complaints and perceived benefits related to drug allergy and interaction alerts 
(Weingart et al., 2009).  The participants of the focus group were physicians, nurse practitioners, 
and practice assistants based in small and medium care practices.  The most appealing features to 
most of the physicians were the refill renewal feature and electronic transmission of the 
prescription.  Uncertainty still remains regarding the reliability issues of prescription 
transmission and dispensing.  For example, electronic transmission of prescriptions may take 
from a few minutes to several hours making it inconvenient for patients; and sometimes due to 
pharmacy’s mismanagement, it creates inconvenience for physicians.  Most of the focus group 
participants questioned safety alerts and considered them as “irrelevant or invalid” (Weingart et 
al., 2009).  However, some of the physicians believed that medication safety alerts provide 
significant information especially while prescribing new and unusual drugs (Weingart et al., 
2009).  Physicians’ preferred systems are desktops and laptops computers compared to personal 
digital assistants (Pizzi et al., 2005). 
Physicians’ Positive Reactions to Electronic Prescribing  
 E-prescribers and non-e-prescribers have different opinions about the benefits of e-
prescribing.  E-prescribing physicians compared to non-e-prescribing physicians strongly believe 
that that e-prescribing is more convenient and it can improve prescribing process efficiency; and 
routing prescriptions electronically is a favorable option especially prescriptions for outpatients 
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(Pizzi et al., 2005).  Additionally, electronic prescribers are also more likely to agree with the 
potential benefits of e-prescribing such that e-prescribing technology helps reduce medication 
and dispensing errors, and saves physicians prescribing time and patients waiting time to receive 
prescriptions (Pizzi et al., 2005).  Moreover, e-prescribers give more importance to 
“improvement of prescription workflow” rather than “return on investment and overall speeding 
of the workflow” (Crosson et al., 2008).  Some other key benefits substantiated by e-prescribers 
are technology which helps reduce drug interactions and helps to regulate patients’ formulary 
therapy.   
Physicians’ Negative Reactions to Electronic Prescribing  
 On the other hand, e-prescribers are not sold on some of the proposed benefits of e-
prescribing like improvements in patient compliance and avoidance of phone usage for 
prescription refills.  Some of the concerns related to e-prescribing technology include cost of the 
system, likelihood of patients not picking up their electronically prescribed medicine leading to 
waste of pharmacy resources, and technology limiting patients’ ability to go to the pharmacy of 
their choice (Pizzi et al., 2005).  Some of the most notable limitations by physicians (e-
prescribers and non e-prescribers) were time involved in learning new technology and correcting 
prescriptions, making work flow changes, pharmacy connectivity issues, patients’ confidentiality 
concerns, effect on physician-patient relationships, lack of organizational support, previous 
negative experiences with technology, prescription fraud/abuses, and belief that pharmaceutical 
companies will use it for marketing purposes (Pizzi et al., 2005).   
 Fisher et al. (2007) found a steady increase in e-prescribing over 12 months.  However, 
physicians failed to achieve full uptake of e-prescribing.  Some of the reasons for incomplete 
uptake of e-prescribing system cited by authors were incapability of accessing e-prescribing from 
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different locations, inability to prescribe controlled substances leading to maintenance of 
duplicates records, and other technical software-related issues (Fischer et al., 2007).  
Additionally, physicians with prior negative experiences are found to be more demanding and 
have very high expectations from the e-prescribing system (Crosson et al., 2007).   
 Physicians’ troubles with e-prescribing emerge from other studies as well.  In one study, 
around 17% of e-prescribers stopped using their e-prescribing system due to network 
connectivity issues, technical and work flow related issues and time because some practices were 
“too busy” to make required workflow changes (Wang et al., 2009).  E-prescribers were also 
unsure about some apparent benefits of the technology like drug history and other patient 
formulary benefit information which are important when large out-of-pocket costs are involved 
(Wang et al., 2009).  In response to these findings, the authors suggest that there should be 
proper exchange of information between payers, health plans and other organizations in order to 
make formulary and benefits information more updated (Wang et al., 2009).   
 Physicians who do not e-prescribe believe that it takes more time writing a prescription 
electronically compared to hand writing it and they also believe that patients are more fond of 
hand prescriptions compared to sending prescriptions electronically (Schectman et al., 2005).  
Campbell et al. (2006) reported some unintended adverse consequences resulting from the use of 
Computerized Provider Order Entry (CPOE) from clinicians’, IT staff, and administrators’ 
perspective.  CPOE goes beyond prescriptions, and enables physicians to optimize ordering of 
medications, laboratory tests, drug-drug interaction alerts, drug-laboratory value checks, among 
others (Agency of Healthcare Research and Quality website).  Unintended consequences 
experienced by clinicians due to the use of CPOE include additional work for clinicians due to 
workflow changes, interference with doctor-patient communication, and the risk of new kinds of 
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errors (wrong selection of the drug from drop down menu).  Some physicians feel over-
dependent on the technology and physicians who are more comfortable writing handwritten 
prescriptions face difficulties in using CPOE (Campbell et al., 2006). 
Physicians’ Barriers to Electronic Prescribing 
 Very few studies have quantified the barriers to e-prescribing perceived by physicians.  
An e-prescribing collaboration project case study in Massachusetts by the Regional Health 
Information Organization for Massachusetts, MA-SHARE, reported early experiences and 
identified the key implementation barriers experienced by the clinicians and office staff in 
hospital settings (Halamka et al., 2006).  Most of the physicians had mixed feelings about e-
prescribing.  On one hand, they believed that e-prescribing helped reduce medication related 
errors and improved the prescribing process by saving time and improving efficiency.  On the 
other hand, workflow issues and product issues such as software and hardware problems 
remained key barriers among physicians.  Some other common barriers experienced by 
physicians during implementation were “previous negative technology experiences, initial and 
long-term cost, lost productivity, competing priorities, change management issues, 
interoperability limitations, information technology (IT) requirements, standards limitations, 
waiting for an “all-in-one solution,” and confusion about competing product offerings including 
hospital/Integrated Delivery System (IDN)–sponsored projects (Halamka et al., 2006). 
 Another study looked at barriers to accepting e-prescribing in United States and tested the 
importance of several constructs like profit and risk factors, shipping and handling, saving, 
customer relationship management, awareness, age, and ethics on individuals’ willingness to 
purchase prescriptions online (Smith, 2006).  The study sample consisted of professional and 
semi-professional service management and Internet users (Smith, 2006).  According to the 
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author, the adoption of e-prescribing has numerous barriers in the pharmacy industry.  The 
acceptance barriers include lack of trust in technology, system costs, and the confidentiality 
issues related to the patients’ health and medical information (Smith, 2006).   
 In summary, the adoption of e-prescribing has slowly increased over a period of time but 
full uptake has still not been achieved.  While the unintended consequences of e-prescribing have 
clearly been identified in the literature, it is critical to assess the factors that physicians find 
encouraging and discouraging about e-prescribing.  This will enable consultants, vendors and 
policymakers to more adequately facilitate the adoption of e-prescribing by directly targeting the 
factors that are most salient to physicians. 
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III. METHODS 
Study Design 
 This study utilized a cross-sectional, descriptive design by means of an Internet-based 
survey administered to a national convenience sample of physicians. 
Sample 
 Sample description.  The sample frame consisted of primary care physicians (PCPs) 
currently practicing in Unites States in the areas of family medicine, general medicine, and 
internal medicine.  Physicians who practice specialty medicine were not recruited for this study.  
This was due to the concern that some specialist physicians may write few outpatient 
prescriptions.  Physicians who write few outpatient prescriptions may be less informative about 
the factors that physicians find encouraging and discouraging about e-prescribing.  In fact, 
physicians who rarely write prescriptions will be exempted by law for the claim of financial 
incentives and penalties for the implementation of e-prescribing for their Medicare patients 
(Medicare Improvements for Patients and Provider Act of 2008).  If specialists comprised a 
considerable percentage of the study sample, post-implementation factors may not be accurately 
representative for physicians who write the bulk of outpatient prescriptions on a weekly basis.  
Therefore, the inclusion of only PCPs was considered appropriate for this study.   
 Sample source.  A national convenience sample of PCPs was obtained from a physician 
panel. 
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 Sample size.  Two resources were used to assess sample size for this study.  When 
conducting a Multivariate Analysis of Variance (MANOVA), Hair et al. (1998, p. 342) 
recommend a minimum cell size of 20 observations.  Given there are five physician categories 
that will be analyzed, a total sample size of 100 respondents is expected to be required.  
However, Hair et al. (1998) also indicates that a greater power requirement will require a greater 
sample size.  G-power estimates that (effect size = 0.25 {medium}, alpha = 0.05, power = 0.80 
and groups = 5) 95 participants are required (19 observations per group) (Faul & Erdfelder, 
2009).   
Data Collection  
 Before pretesting the questionnaire, approval by the University of Mississippi 
Institutional Review Board was obtained.  Subsequently, the survey was pre-tested among 
graduate students to assess the clarity of instructions and the time required for completion.  
Additionally, it was pre-tested among campus physicians for the same assessment.  For the final 
study, physicians were recruited with an email that included a cover letter (Appendix A) and a 
link for the corresponding electronic survey (Appendix B).  The survey link remained available 
until an adequate number of physicians completed the survey.  One of the concerns when using 
an Internet-based survey and physician panel is that it leads to over-sampling of technology-
savvy users.  This may be particularly concerning when conducting a study of e-prescribing.  
However, the primary objective of this study was to determine the factors that physicians find 
encouraging and discouraging about e-prescribing.  There are many factors that are not related to 
technology like cost and time to install that have been identified.  Additionally, one previous 
study using an Internet-based survey indicated that 14% of physician respondents were electronic 
prescribers and 86% of the respondents were traditional prescribers (Pizzi et al., 2005); 
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suggesting that physicians who complete electronic survey are not necessarily more likely to be 
e-prescribers. 
Measures 
 Factors that physicians find encouraging and discouraging about e-prescribing.  The 
first objective of this study was to determine the factors that physicians find encouraging and 
discouraging about e-prescribing. Potential factors physicians perceive about e-prescribing were 
identified from the relevant e-prescribing literature.  They were categorized by the investigator 
into nine groups including: 1) cost, 2) time, 3) personnel, 4) work flow, 5) external influences, 6) 
technology, 7) patients, 8) features, and 9) policy. Table 2 lists identified factors including their 
sources.  The extent to which factors were encouraging or discouraging was measured using an 
11 – point bipolar scale from -5 to +5 where -5 = “greatly discourages me”, +5 = “greatly 
encourages me” and 0 = “does not affect me”.  We also collected qualitative data by allowing 
physicians to offer additional comments on these factors (if any) for future data analysis. 
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Table 2: List of Influencing Factors and Their Sources 
Factors related to electronic prescribing Cited articles 
COST 
Initial cost of implementation Halamka et al., 2006  
Pizzi et al., 2005 
Financial cost of updating/upgrading the e-
prescribing system  
Halamka et al., 2006 
Pizzi et al., 2005 
Return on investment related to e-prescribing Crosson et al., 2007 
TIME  
Process of entering existing patient medical 
history into the e-prescribing system during 
initial implementation 
eHealth Initiatives Report, 2008 
Process of entering new patient medical history 
into the e-prescribing system when you see a 
new patient 
eHealth Initiatives Report, 2008 
Process of learning and installing a new e-
prescribing system 
Pizzi et al., 2005 
Process of creating customized templates in an 
e-prescribing system 
  
Process of selecting an appropriate vendor and 
system for my practice 
Halamka et al., 2006 
Time taken to complete an electronic 
prescription 
Wang et al., 2009  
Campbell et al., 2006 
Time required for an electronic prescription to 
reach the pharmacy 
Weingart et al., 2009 
PERSONNEL 
Training staff/clinicians on a new e-prescribing 
system 
Pizzi et al., 2005 
Availability of organizational and staff support 
during e-prescribing implementation 
Pizzi et al., 2005 
WORK FLOW 
Process of infrastructure/workflow redesign 
while implementing e-prescribing 
Pizzi et al., 2005 
Effect on productivity during e-prescribing 
implementation 
Halamka et al., 2006  
Pizzi et al., 2005 
Effect on productivity after e-prescribing 
implementation 
Halamka et al., 2006 
 Pizzi et al., 2005 
Comfort level with writing electronic 
prescriptions 
  
EXTERNAL INFLUENCES 
Availability of appropriate vendors and systems 
for my practice 
  
The lack of adoption of e-prescribing by other Halamka et al., 2006 
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physicians 
Government education/awareness initiatives to 
promote e-prescribing 
Surescripts Report 2009 
E-prescribing software vendors promotion of e-
prescribing 
  
TECHNOLOGY 
Fisher et al., 2008, Halamka et al., 
2006, Pizzi et al., 2005,  
Campbell et al., 2006 
Effect on overall prescribing error rates due to 
e-prescribing  
Weingart et al., 2009 
Campbell et al., 2006 
Access of e-prescribing systems from different 
locations 
Fisher et al., 2008 
Availability of Electronic Medical 
Records/Electronic Health Records that 
incorporate e-prescribing 
Halamka et al., 2006 
Number of pharmacies participating in e-
prescribing 
Pizzi et al., 2005  
Wang et al., 2009  
American Medical Association, 2008 
Number of payers connected to e-prescribing 
technology 
Wang et al., 2009 
Security of electronically sent prescriptions Pizzi et al., 2005 
Quality of currently available e-prescribing 
software 
  
The need for high speed Internet for the 
transmission of an electronic prescription 
Halamka et al., 2006  
Wang et al., 2009 
Availability of software that supports the current 
workflow in my practice 
Halamka et al., 2006 
PATIENTS  
Ability to maintain patient confidentiality when 
e-prescribing 
Pizzi et al., 2005 
Effect of e-prescribing on patients’ likelihood to 
pick up their medication from the pharmacy 
Pizzi et al., 2005 
Effect of e-prescribing on the physician-patient 
conversation during the visit 
Pizzi et al., 2005 
Effect of patients’ perceptions on my use of e-
prescribing technology 
  
FEATURES 
Availability of patient medical history in the 
electronic prescribing system 
eHealth Initiatives Report, 2008 
Availability of comprehensive patient insurance 
eligibility information 
eHealth Initiatives Report, 2008 
Availability of comprehensive formulary 
information 
Pizzi et al., 2005 
Availability of safety drug alerts during e-
prescribing 
Weingart et al., 2009 
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Availability of refill function in the e-
prescribing system 
  
Availability of feedback from pharmacy 
regarding patient compliance during refills 
  
Availability of prescription receipt confirmation 
from the pharmacy 
  
POLICY 
Ongoing policy changes related to e-prescribing   
Availability of national standards related to e-
prescribing 
Halamka et al., 2006 
Medicare’s monetary incentives for e-
prescribing adoption 
Medicare Improvements for Patients 
and Providers Act of 2008 
Medicare’s monetary disincentives for e-
prescribing adoption 
Medicare Improvements for Patients 
and Providers Act of 2008 
 
Electronic prescribing adoption status.  The second objective of this study was to 
compare the factors that physicians find encouraging and discouraging about e-prescribing based 
on their e-prescribing adoption status.  While it may be helpful to have respondents indicate 
whether or not they e-prescribe, it may actually be more useful to place physicians into more 
specific categories of e-prescribing adoption status.  Above and beyond knowing whether a 
physician has adopted e-prescribing, knowing more specific details about their adoption status 
may better help consulting firms and policymakers whose goal is to encourage and promote e-
prescribing to better target these physicians.  Interestingly, Pizzi et al. (2005) used the 
Transtheoretical Model of Change (TTM) for the purpose of simply categorizing physicians into 
stages of adoption (and did not conduct further analysis once respondents were categories.  
While their approach to categorization posed some limitations (as will be discussed 
forthcoming), there appears to be value in using TTM to place physicians in specific stages of 
adoption.   
 According to Prochaska and Velicer (1997), TTM consists of six stages of changes 
including (precontemplation, contemplation, preparation, action, maintenance, and termination) 
23 
 
and ten processes of changes (consciousness raising, counter conditioning, dramatic relief, 
environmental reevaluation, helping relationships, reinforcement management, self-liberation, 
self-reevaluation, social liberation, and stimulus control).  In the TTM (based initially on 
research in health and mental health behavior), Prochaska and colleagues have identified stages 
that individuals typically go through in the process of change, from pre-contemplation (when 
there is no intent to change), to contemplation (where there is intent to change), to preparation 
(when individuals intend to take action in immediate future and have taken some behavioral 
steps in this direction), to action (individuals have changed overt behavior), to maintenance 
(when they have changed their behavior for more than six months to five years), and finally to 
termination (individuals have no temptation and 100% self-efficacy to stay in their behavior).  
The termination stage is considered an ideal stage for the majority of individuals (Prochaska & 
Velicer, 1997).  However, the termination stage does not apply to all interventions such as 
weight loss or completing a course of medication and is not used often due to the stringent 
criteria that define this stage (Prochaska et al., 2002). 
 Over time, TTM has been utilized in behavior studies of “alcohol and substance abuse, 
anxiety and panic disorders, delinquency, eating disorders and obesity, high-fat diets, HIV/AIDS 
health behavior and health education prevention, mammography screening, medication 
compliance, unplanned pregnancy prevention, pregnancy and smoking, sedentary lifestyles, sun 
exposure, and physicians practicing preventive medicine” (Prochaska et al., 2002).   
 As previously noted, Pizzi et al.’s (2005) use of TTM to classify physicians with regard 
to e-prescribing bears several limitations.  First, they did not allow for an action stage (have been 
using an electronic prescribing system for less than 6 months), but rather, skipped from the 
preparation stage (ready to make the change) to the maintenance stage (sustaining the behavior 
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after it has been changed).  This study is interested in discerning the difference between the 
action and maintenance stages, and this would likely have implications for e-prescribing 
interventions by consulting firms and policymakers.  Pizzi et al.’s (2005) adaptation of TTM also 
did not incorporate the concept of relapse (returning to earlier stages for action and maintenance) 
which is not a stage, but rather, a form of regression.  Examination of the e-prescribing literature 
suggests that several physicians have stopped using the system after implementation, and some 
of those planned to adopt again (Crosson et al., 2007).  Therefore, it appears justified to include 
relapse in our adaption of TTM.  Finally, Pizzi et al. (2005) did not incorporate a time frame for 
each TTM stage as presented by Prochaska and Velicer (1997).  It is believed that presenting a 
time frame to respondents is important for the accurate staging of respondents.  A summary of 
Pizzi et al.’s (2005) adaptation of the TTM for the use in their study is provided in Table 3. 
Table 3: Stages of Transtheoretical Model of Change Used by Pizzi et al. (2005) 
Stages of 
Transtheoretical 
Model of Change 
Description Item presented to respondents 
Precontemplation 
 
No intention to use E 
RX 
 I have not considered using electronic 
prescribing 
Contemplation 
 
Intention to use E RX 
but not ready to do so 
 I have considered using electronic 
prescribing, but I am not ready to do so 
Preparation Ready to use E RX in 
the foreseeable future 
I have considered using electronic 
prescribing, and I am ready to begin 
doing it 
Maintenance Already using E RX I currently prescribe electronically for 
outpatients 
Source: Pizzi et al., 2005 
 In the adaption of TTM used for this study, the following steps were taken.  An item for 
the precontemplation stage was presented to respondents as conceptualized.  In addition, to 
differentiate respondents according to whether they have or have not considered using electronic 
prescribing (and have no intention of adapting it in the next six months), one extra stage “during-
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contemplation” was added.  It is believed that discerning as to whether the respondents have or 
have not considered electronic prescribing has important implications for future interventions.  
Items for precontemplation, contemplation, preparation, action, and maintenance stages were 
created for their respective stages as conceptualized (Table 4).  
 Relapse, which is a form of regression and not a stage (Prochaska & Velicer, 1997), was 
assessed as a separate stage in this study.  Those physicians who selected the relapse stage were 
then asked to select one of the five stages to capture their current state of adoption (i.e. whether 
they are considering, intending or ready to adopt again, or already using) and was addressed as 
such during analysis.  Table 4 summarizes stages of adoption as applied to this study. 
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Table 4: Stages of Transtheoretical Model of Change Applied to this Study 
Stages of 
Transtheoretical 
Model of Change 
Description Questions asked regarding 
current status 
Precontemplation 
 
In this stage individuals have no 
intention to take action in 
foreseeable future (usually 
within the next six months). 
1. My practice has not 
considered using electronic 
prescribing and has no 
intention of adopting it in the 
next 6 months 
During-
contemplation 
 2. My practice has considered 
using electronic prescribing 
and has no intention of 
adopting in the next 6 months 
Contemplation 
 
In this stage individuals intend 
to take action within the next 
six months. 
 
3. My practice is not planning 
to implement it in the next 30 
days, but is planning to 
implement it in the next 6 
months     
Preparation In this stage individuals intend 
to take action in the immediate 
future (within the next thirty 
days) and have taken some 
behavioral steps in this 
direction. 
4. My practice is currently in 
the process of implementing 
or planning to implement it 
in less than 30 days 
Action In this stage individuals have 
changed overt behavior for less 
than six months. 
 
5. My practice has been using 
an electronic prescribing 
system for outpatient 
prescriptions for less than 6 
months 
Maintenance In this stage individuals have 
changed their behavior for more 
than six months and they are 
less likely to relapse compared 
to action stage. 
6. My practice has been using 
an electronic prescribing 
system for outpatient 
prescriptions for more than 6  
months 
Relapse Individuals in this stage return 
to their earlier stages 
7. Regardless of your current use 
of e-prescribing, have you 
ever started and stopped using 
e-prescribing in the past? 
Source: Prochaska and Velicer, 1997 
 Demographic characteristics. The third objective of this study was to determine which 
demographic factors are significant predictors of physicians’ perceptions about factors that are 
encouraging and discouraging about e-prescribing.  As mentioned in the literature review, the 
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demographic characteristics play an important role and have been significantly correlated with 
the adoption of electronic prescribing.  The demographic characteristics that was collected for 
this study include:  1) gender, 2) age, 3) years in practice, 4) years left in practice, 5) geographic 
location (Northeast, Midwest, South, West), 6) practice type, 7) practice setting, 8) rural/urban 
location of the practice, 9) practice size (number of full time equivalent {FTE} physicians), 10) 
number of nurses in the practice, 11) number of patients seen per week, and, 12) number of 
outpatient prescriptions written per week. 
 Adoption category traits as outlined by Rogers, (1995). Rogers, (1995) classifies 
innovators and their willingness to adopt new technology in five groups: 1) innovators, 2) early 
adopters, 3) early majority, 4) late majority, and 5) laggards.  These adoption categories were 
measured to identify innovation adoption traits by physicians. The item-scales to assess these 
five groups were adopted from Savery, (2005).  Savery, (2005) used ten items with a 4-point 
Likert-type scale to assess how public relations practitioners perceive their level of 
innovativeness. Table 5 summarizes adoption categories (Rogers, 1995) and respective items 
used by Savery, 2005.  Data collected from this measure were not utilized for the particular 
objectives of this study, but will be used for future data analysis. 
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Table 5: Adoption categories (Rogers, 1995) and Items Used by Savery, 2005 
Adoption 
categories 
Item presented to respondents by Savery, 2005 and 
Questions asked regarding adoption category traits in this study 
1. Innovators 1. I am venturesome and eager to be the first to try new 
innovations. 
2. I am always looking for innovations. 
2. Early adopters 3. I adopt innovations and influence others to do so. 
4. My opinion about innovations is respected by peers. 
3. Early majority 5. I am willing to follow the lead of others in adopting innovations. 
6. I will adopt innovations but do not attempt to influence others to 
do so. 
4. Late majority 7. I need to be convinced of the advantage of innovations by peers. 
8. I go along with innovations out of necessity. 
5. Laggards 9. I am suspicious of innovations. 
10. I am resistant to change. 
Source: Rogers, (1995) and Savery, (2005) 
 Electronic prescribing systems.  A question regarding the software/hardware currently 
being used (or planned to be used in the future) was asked to all physicians except those have not 
considered using electronic prescribing and have no intention of adopt it in next six months.  An 
open-ended question was employed so that physicians may indicate what products they are 
using.  Data collected from this measure were not utilized for the particular objectives of this 
study, but will be used for future data analysis.  In addition, transition time (in months) taken by 
practice and staff to adopt e-prescribing was assessed only among physicians who are currently 
using the e-prescribing system (action and maintenance stage).  Moreover, whether physicians 
have received any free software from vendor or government and whether they have integrated e-
prescribing software with EHR/EMR or standalone e-prescribing software was also included in 
this study and answered by physicians who are currently using the e-prescribing system.  E-
prescribers were asked about what type of e-prescribing system they are using at their practice 
and their most preferred e-prescribing software.  Secondly, it was asked whether e-prescribers 
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have encountered any problems with the software they are currently using, and if so, what 
specific problems they have encountered.  Lastly, e-prescribers were asked their preferred 
method for prescribing medication (electronic prescribing or traditional prescribing).  
 Satisfaction with electronic prescribing system.  A question about physicians’ satisfaction 
with their e-prescribing system was asked only to physicians who are currently using or have 
adopted the e-prescribing.  Satisfaction with the e-prescribing system was measured with the 
anchors delighted, mostly satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly 
dissatisfied, mostly dissatisfied, and terrible (Dillman, 2007 p. 97-98).  
 Medicare incentives and disincentives.  In addition, the influence and knowledge of 
Medicare incentives and disincentives was measured using a 5 – point scale where, 1 = not at all 
influential and 5 = very influential.  Data collected from this measure were not utilized for the 
particular objectives of this study, but will be used for future data analysis. 
 Physician involvement in decision making processes of adopting new technology. The 
extent of involvement in decision making process was measured using a 5 – point scale where, 1 
= being to a great extent and 5 = being to a least extent.  In addition, physicians’ extent of 
agreement/disagreement with the decision to adopt/not adopt electronic prescribing in their 
practice was measured using a 5-point agreement sale. 
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Analysis  
 Sample description.  A description of the sample was provided using the twelve 
demographic variables previously described by calculating means, frequencies, and percentages, 
as appropriate.  Data were presented in six adoption categories. 
 Descriptive statistics.  Frequencies were calculated to determine the number of 
physicians that have placed themselves into each adoption stage.  Similarly, frequencies were 
calculated to evaluate adoption category traits, satisfaction with e-prescribing system, and 
software/hardware currently used by physicians.  Finally, a mean was calculated to assess 
months required being fully functional on e-prescribing system. 
 Principal component analysis.  Because the items comprising the encouraging and 
discouraging factors were collected from e-prescribing literature and were not acquired from a 
previously established scale, principal component analysis (PCA) using VARIMAX rotation was 
used to preliminarily describe the factor structure of the encouragement/discouragement 
measure. 
 Reliability.  The internal consistency, or reliability, of the scales comprising each of the 
factors identified in the above PCA was calculated using Cronbach’s alpha. 
 Objective 1.  The first objective of this study was to determine the factors that physicians 
find encouraging and discouraging about e-prescribing.  Means were calculated for each scale of 
the influencing factor measure identified during principal components analysis for all 
respondents as a whole.  Additionally, an overall mean for the entire factor measure was reported 
for all response as a whole.  
 Objective 2. The second objective of this study was to compare the factors that physicians 
find encouraging and discouraging about e-prescribing based on their specific e-prescribing 
adoption status.  This was accomplished by conducting a Multivariate Analysis of Variance 
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(MANOVA).  Assumptions of MANOVA including independence of observations, homogeneity 
of variance-covariate matrices and normality were addressed prior to conducting the MANOVA. 
 Objective 3.  The third objective of this study was to determine which demographic 
factors are significant predictors of physicians’ perceptions of factors that are encouraging and 
discouraging about e-prescribing.  To address third objective, twelve demographics 
characteristics were tested for their ability to predict physicians’ perceptions (on the overall 
scale) using multiple linear regression with alpha = 0.05. 
  
32 
 
IV. RESULTS 
Sample Description  
 Responses were received from 444 physicians.  One respondent was removed from the 
sample as this physician reported to not write outpatient prescriptions (an inclusion criterion of 
the study); therefore resulting in 443 useable responses.  The average age of the physician 
respondents was 51 years, and over half of the respondents practiced in family or general 
medicine (53.5%).  Around three-quarters of the respondents were male (77.4%), owned a 
private practice (70.2%) and practiced in rural areas (83.7%) based on Rural Urban Commuting 
Area (RUCA) codes.   Respondents reported practicing medicine (post-residency) for an average 
of 20 years and were planning to practice medicine for an average of 15 more years.  
Respondents’ geographic location was fairly distributed across the four major regions of the 
United States.  A full sample description organized by self-reported e-prescribing adoption status 
is provided in Table 6.  
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Table 6: Sample Description 
 
Current Status 
Total Group 1 
Adopted  
> 6 Months 
Group 2 
Adopted  
< 6 Months 
Group 3 
In Process 
< 1 Month 
Group 4 
In Process 
In 6 Months 
Group 5 
Considered, No 
Intention 
Group 6 
Not 
Considered, 
No Intention 
n % n % n % n % n % n % n % 
Gender 
Male 181 78.0 22 88.0 26 76.5 45 71.4 39 76.5 30 78.9 343 77.4 
Female 51 22.0 3 12.0 8 23.5 18 28.6 12 23.5 8 21.1 100 22.6 
Practice Type 
Family/General 
Medicine 
131 57.3 11 44.0 12 35.3 30 47.6 28 54.9 23 60.5 237 53.5 
Internal Medicine 86 37.1 12 48.0 19 55.9 29 46.0 19 37.3 10 26.3 175 39.5 
Other 13 5.6 2 8.0 3 8.8 4 6.3 4 7.8 5 13.2 31 7.0 
Practice Setting 
Private Practice 156 67.2 17 68.0 27 79.4 45 71.4 37 72.5 29 76.3 311 70.2 
Hospital Owned-Office 
Based 
49 21.1 6 24.0 2 5.9 13 20.6 11 21.6 4 10.5 85 19.2 
Hospital-Based 4 1.7 1 4.0 2 5.9 2 3.2 2 3.9 2 5.3 13 2.9 
Outpatients/ 
Community 
4 1.7 0 0.0 1 2.9 1 1.6 1 2.0 3 7.9 10 2.3 
Group/Staff HMO 5 2.2 0 0.0 1 2.9 0 0.0 0 0.0 0 0.0 6 1.4 
Academic/University 
Health Center 
10 4.3 1 4.0 0 0.0 1 1.6 0 0.0 0 0.0 12 2.7 
County Health 
Department 
1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 
Community Health 
Center 
3 1.3 0 0.0 1 2.9 1 1.6 0 0.0 0 0.0 5 1.1 
Population Area 
Urban 194 84.3 17 68.0 28 82.4 54 85.7 44 86.3 32 84.2 369 83.7 
Rural 36 15.7 8 32.0 6 17.6 9 14.3 7 13.7 6 15.8 72 16.3 
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Table 6 (cont): Sample Description 
 
Current Status 
Total Group 1 
Adopted  
> 6 Months 
Group 2 
Adopted  
< 6 Months 
Group 3 
In Process 
< 1 Month 
Group 4 
In Process 
In 6 Months 
Group 5 
Considered, No 
Intention 
Group 6 
Not Considered, 
No Intention 
 n % n % n % n % n % n % n % 
Geographic Location 
Northeast 60 25.9 9 36.0 5 14.7 15 23.8 12 23.5 10 26.3 111 25.1 
Midwest 69 29.7 5 20.0 7 20.6 17 27.0 11 21.6 9 23.7 118 26.6 
South 72 31.0 7 28.0 11 32.4 22 34.9 21 42.2 12 31.6 145 32.7 
West 31 13.4 4 16.0 11 32.4 9 14.3 7 13.7 7 18.4 69 15.6 
Practice Size 
Solo practice 49 21.1 4 16.0 13 38.2 20 31.7 23 45.1 20 52.6 129 29.1 
2 32 13.8 4 16.0 5 14.7 6 9.5 7 13.7 4 10.5 58 13.1 
3 35 15.1 3 12.0 2 5.9 9 14.3 9 17.6 3 7.9 61 13.8 
4-5 39 16.8 7 28.0 6 17.6 10 15.9 6 11.8 6 15.8 74 16.7 
6-15 41 17.7 4 16.0 5 14.7 10 15.9 5 9.8 4 10.5 69 15.6 
> 16 36 15.5 3 12.0 3 8.8 8 12.7 1 2.0 1 2.6 52 11.7 
Number of Nurses in the Practice 
0 49 21.1 8 32.0 9 26.5 17 27.0 16 31.4 17 44.7 116 26.2 
1 34 14.7 2 8.0 7 20.6 7 11.1 11 21.6 7 18.4 68 15.3 
2 29 12.5 1 4.0 4 11.8 10 15.9 8 15.7 2 5.3 54 12.2 
3 16 6.9 4 16.0 5 14.7 3 4.8 5 9.8 4 10.5 37 8.4 
4-5 39 16.8 4 16.0 5 14.7 10 15.9 3 5.9 3 7.9 64 14.4 
6-10 26 11.2 2 8.0 2 5.9 7 11.1 5 9.8 1 2.6 43 9.7 
> 10 39 16.8 4 16.0 2 5.9 9 14.3 3 5.9 4 10.5 61 13.8 
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Table 6 (cont): Sample Description 
 
Current Status 
Total Group 1 
Adopted  
> 6 Months 
Group 2 
Adopted  
< 6 Months 
Group 3 
In Process 
< 1 Months 
Group 4 
In Process 
In 6 Months 
Group 5 
Considered, No 
Intention 
Group 6 
Not Considered, 
No Intention 
 n % n % n % n % n % n %  % 
Number of Outpatient Prescriptions Written Per Week 
1-50 25 10.8 2 8.0 2 5.9 9 14.3 4 7.8 7 18.4 49 11.1 
51-100 36 15.5 7 28.0 8 23.5 11 17.5 11 21.6 9 23.7 82 18.5 
101-150 42 18.1 3 12.0 2 5.9 11 17.5 10 19.6 4 10.5 72 16.3 
151-200 39 16.8 5 20.0 6 17.6 9 14.3 5 9.8 3 7.9 67 15.1 
200-300 53 22.8 4 16.0 9 26.5 13 20.6 9 17.6 12 31.6 100 22.6 
> 300 37 15.9 4 16.0 7 20.6 10 15.9 12 23.5 3 7.9 73 16.5 
Number of Outpatients Seen Per Week 
1-50 15 6.5 4 16.0 1 2.9 3 4.8 1 2.0 6 15.8 30 6.8 
51-75 23 9.9 3 12.0 3 8.8 8 12.7 4 7.8 3 7.9 44 9.9 
76-100 84 36.2 8 32.0 7 20.6 24 38.1 22 43.1 12 31.6 157 35.4 
101-125 55 23.7 5 20.0 8 23.5 11 17.5 7 13.7 7 18.4 93 21.0 
126-150 24 10.3 4 16.0 6 17.6 10 15.9 10 19.6 6 15.8 60 13.5 
> 150 31 13.4 1 4.0 9 26.5 7 11.1 7 13.7 4 10.5 59 13.3 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Age 50.82 8.23 53.60 6.67 48.21 7.74 51.02 9.06 51.90 8.62 54.95 9.42 51.28 8.49 
Years in practice 20.06 8.47 22.12 7.47 16.09 6.73 20.06 8.66 20.82 8.30 22.92 8.86 20.21 8.42 
Years Left To Practice 15.28 7.77 14.00 9.71 19.12 9.28 14.14 9.14 14.92 8.38 13.89 8.64 15.18 8.40 
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Descriptive Statistics 
 E-prescribing status.  The current electronic prescribing status of respondents is 
presented in Table 7.  Most of the respondents (52.4%) reported using e-prescribing technology 
for more than 6 months (maintenance stage) and 5.6% of the physicians reported using e-
prescribing technology for less than 6 months (action stage).  However, about 20% of the 
respondents reported that they have no intention of using e-prescribing in near future (pre-
contemplation and during-contemplation stages).  8.6% of the physicians have not even 
considered and have no intention of using e-prescribing technology for their practice (pre-
contemplation stage).  Finally, about 21.9% of physicians are intending to adopt e-prescribing 
within one to six months (contemplation and preparation stage). 
Table 7:  Respondents’ Current E-Prescribing Status 
  
Current Status 
Maintenance Action Preparation  Contemplation 
During 
Contemplation 
Pre-contemplation 
Group 1 
Adopted  
> 6 Months 
Group 2 
Adopted  
< 6 Months 
Group 3 
In Process 
< 1 Months 
Group 4 
In Process 
In 6 Months 
Group 5 
Considered, No 
Intention 
Group 6 
Not Considered, 
No Intention 
n 232 25 34 63 51 38 
% 52.4% 5.6% 7.7% 14.2% 11.5% 8.6% 
 
Respondents who have started and stopped e-prescribing.  Ninety-eight (22.1%) 
respondents started and stopped (relapsed) using e-prescribing in the past regardless of their 
current e-prescribing status (Table 8).  Reasons provided by respondents for discontinuing e-
prescribing in the past were hardware problems (12.4%), software problems (34.0%), workflow 
problems (27.9%), and other problems (25.5%).  These other problems would include cost 
issues, time consumption, lack of pharmacy connections, etc.  Other respondents indicated that a 
change in job or practice was the reason that they stopped e-prescribing, not necessarily a 
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problem with e-prescribing, itself.  Among these “relapsers”, just over half (54%) returned to e-
prescribing and about 26% are planning to return to e-prescribing in the next one to six months. 
 
Table 8: Number of Respondents Reporting to Relapse with E-Prescribing 
Relapse 
Current Status 
TOTAL Group 1 
Adopted  
> 6 Months 
Group 2 
Adopted  
< 6 Months 
Group 3 
In Process 
< 1 Months 
Group 4 
In Process 
In 6 Months 
Group 5 
Considered, 
No Intention 
Group 6 
Not 
Considered, 
No Intention 
 n % n % n % n % n % n % n % 
Yes 51 22.0 8 32.0 9 26.5 17 27.0 8 15.7 5 13.2 98 22.1 
No 181 78.0 17 68.0 25 73.5 46 73.0 43 84.3 33 86.8 345 77.9 
 
 Influence over decision-making.  Respondents were also asked to report the extent of 
their involvement in key decision making for e-prescribing implementation (1 = none and 5 = to 
a great extent) and whether they consider themselves to be a key decision maker for e-
prescribing implementation.  Reported mean involvement was 3.45 (±1.51) which suggests that 
respondents were involved in the key decision making process. Additionally, about 60% of the 
physicians reported that they were the key decision makers for e-prescribing implementation.  
Cross-tabulations and associated chi square tests indicate statistically significant differences (p < 
.05) in frequencies of key decision makers among respondents according to their e-prescribing 
status (Table 9) and practice size (Table 10).   
Table 9:  Number of Key Decision Makers in Each Adoption Status Group 
Key decision 
maker for e-
prescribing 
implementation 
Current Status 
TOTAL Group 1 
Adopted 
> 6 Months 
Group 2 
Adopted 
<6 Months 
Group 3 
In process 
< 30 days 
Group 4 
In process 
In 6 Months 
Group 5 
Considered, 
No Intention 
 N % N % N % N % N % N % 
Yes 131 56.5% 12 48% 25 73.5% 37 58.7% 38 74.5% 243 60% 
No 101 43.5% 13 52% 9 26.5% 26 41.3% 13 25.5% 162 40% 
 * Significant at alpha 0.05 
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Table 10:  Number of Key Decision Makers in Each Category of Practice Size 
Key Decision 
Maker for e-
prescribing 
implementation 
Practice Size 
Total Solo 
practice 
Two 
Physicians 
Three 
Physicians 
4 – 5 
Physicians 
6 -15 
Physicians 
More than 
16 
physicians 
 N % N % N % N % N % N % N % 
Yes 
92 84.4% 38 70.4% 33 56.9% 36 52.9% 29 44.6% 15 29.4% 243 60% 
No 
17 15.6% 16 29.6% 25 43.1% 32 47.1% 36 55.4% 36 70.6% 162 40% 
 * Significant at alpha 0.05 
 Respondents’ experience with e-prescribing.  Among respondents currently e-prescribing 
(n = 257), most respondents (n = 214) indicated satisfaction with their e-prescribing system.  
More than half of respondents indicated that their e-prescribing software was integrated with 
electronic medical records (54.1%).  Additionally, most physicians preferred tablet/laptop 
personal computers (45.1%) and desktop personal computers (48.2%) as their e-prescribing 
hardware.  The preference for prescribing stated by physicians using e-prescribing was 
predominantly electronic prescribing (81.7%) compared to traditional prescribing (18.3%).  
Additional characteristics of the e-prescribers can be found in Table 11. 
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Table 11:  Respondents’ Experience with E-Prescribing (N=257) 
Characteristics 
Number of Respondents 
(%) 
Satisfaction with their current e-prescribing system 
Completely satisfied 37 (14.4) 
Mostly satisfied 142 (55.3) 
Slightly satisfied 35 (13.6) 
Neither satisfied nor dissatisfied 11 (4.3) 
slightly dissatisfied 17 (6.6) 
mostly dissatisfied 13 (5.1) 
completely dissatisfied 12 (0.8) 
Received free e-prescribing system 
Yes 56 (21.8) 
No 201 (78.2) 
Standalone vs. Integrated e-prescribing system 
Standalone e-prescribing software 71 (27.6) 
Integrated e-prescribing software with electronic 
health records 
39 (15.2) 
Integrated e-prescribing software with electronic 
medical records 
139 (54.1) 
Other 8 (3.1) 
Type of e-prescribing system used 
Handheld devices 39 (10.8) 
Tablet/laptop personal computers 149 (41.3) 
Desktop personal computers 172 (47.6) 
Other hardware 1 (0.3) 
Most preferred type of e-prescribing system  
Handheld devices 16 (6.2) 
Tablet/Laptop personal computers 116 (45.1) 
Desktop personal computers 124 (48.2) 
Other hardware  1 (0.4) 
Encountered any problems with the software* 
Yes 138 (53.7) 
No 106 (41.2) 
Primary preference for prescribing 
Electronic prescribing 210 (81.7) 
Traditional prescribing 47 (18.3) 
 
 
Mean (SD) 
Months in transition to the point of being fully 
functional 
4.04 (7.30) 
 * 13 (5.1%) of e-prescribing respondents chose not to answer this question 
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Principal Component Analysis 
 The 44 e-prescribing items that respondents rated as encouraging or discouraging were 
primarily identified in the e-prescribing literature, and were not acquired from previously 
established scales. Therefore, principal component analysis (PCA) with VARIMAX rotation was 
conducted.   As a result of this analysis, seven components of the scale were identified included 
pre-implementation factors (9 items), technology factors (9 items), features (7 items), external 
influences (8 items), patient factors (4 items), post-implementation factors (4 items), and cost 
factors (3 items). Standardized coefficients from the rotated factor matrix representing the 
loading of each item to the component to which it was assigned is shown in Table 12.   
Reliability 
 Reliability of the seven components obtained from the PCA was calculated using 
Cronbach’s alpha.  Table 12 lists all seven components and their associated items along with 
their Cronbach’s alpha coefficients, the summated means and standard deviations of the scale 
scores, and the per-item means for each scale.  Cronbach’s alpha of the overall scale was 0.967 
with summated mean and standard deviation of 28.67 ± 68.75.   Cronbach’s alpha, if any of the 
items were deleted, was also evaluated for all seven components.  No action was taken on pre-
implementation factors, patient factors, and cost factors.  The Cronbach’s alpha of the 
technology scale was 0.926; however, two of the items in technology factors, “the need for high 
speed Internet for the transmission of an electronic prescription” and “availability of software 
that supports the current workflow in my practice” had low standardized coefficients (0.483 and 
0.484, respectively) in the PCA results.  For that reason, reliability was reassessed without these 
two variables. As a result of item removal, the Cronbach’s alpha was found to be lower (0.914 
vs. 0.926).  Similar results were seen when reliability was re-assessed without one of the features 
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items, “availability of patient medical history in the electronic prescribing system” and one of the 
post-implementation items “time taken to complete an electronic prescription” with low 
standardized coefficients (0.530 and 0.524) in their respective scales.   Therefore, these four 
items were left in their respective scales.    After reassessing reliability without the items “the 
lack of adoption of e-prescribing by other physicians” item from the external influences factor 
(standardized coefficient = 0.484), the Cronbach’s alpha increased very little (from 0.888 to 
0.897).  Therefore, no action was taken.  In conclusion, all 44 of the items were included after 
assessing reliability and were used to further test the objectives of this study. 
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Table 12: Principal Component Analysis and Reliability Results 
Items 
Number 
of Items 
Standardized 
Coefficients 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Cronbach’s 
Alpha 
Means ± SD 
Per-
Item 
Mean 
Component 1 – Pre-Implementation Factors 9 
 
0.945 -6.49 ± 19.34 -0.72 
Process of learning and installing a new e-prescribing system 
 
0.831 
   
Process of entering new patient medical history into the e-prescribing system when you see 
a new patient 
0.782 
Process of entering existing patient medical history into the e-prescribing system during 
initial implementation 
0.745 
Process of selecting an appropriate vendor and system for my practice 0.743 
Process of creating customized templates in an e-prescribing system 0.741 
Training staff/clinicians on a new e-prescribing system 0.717 
Process of infrastructure/workflow redesign while implementing e-prescribing 0.700 
Effect on productivity during e-prescribing implementation 0.687 
Availability of organizational and staff support during e-prescribing implementation 0.620 
Component 2 – Technology Factors 9 
 
0.926 11.47 ± 17.13 1.27 
Access of e-prescribing systems from different locations 
 
0.739 
   
Number of pharmacies participating in e-prescribing 0.739 
Availability of Electronic Medical Records/Electronic Health Records that incorporate e-
prescribing 
0.717 
Number of payers connected to e-prescribing technology 0.685 
Security of electronically sent prescriptions 0.639 
Effect on overall prescribing error rates due to e-prescribing  0.632 
Quality of currently available e-prescribing software 0.564 
Availability of software that supports the current workflow in my practice 0.484 
The need for high speed Internet for the transmission of an electronic prescription 0.483 
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Table 12 (cont): Principal Component Analysis and Reliability Results 
Items 
Number 
of Items 
Standardized 
Coefficients 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Cronbach’s 
Alpha 
Mean ± SD 
Per-
Item 
Mean 
Component 3 – Features  7 
 
0.891 16.42 ± 12.23 2.35 
Availability of feedback from pharmacy regarding patient compliance during refills 
 
0.792 
   
Availability of comprehensive formulary information 0.789 
Availability of prescription receipt confirmation from the pharmacy 0.788 
Availability of safety drug alerts during e-prescribing 0.768 
Availability of comprehensive patient insurance eligibility information 0.736 
Availability of refill function in the e-prescribing system 0.633 
Availability of patient medical history in the electronic prescribing system 0.530 
 
 Component 4 – External Influences  
8 
 
0.888 0.85 ± 13.73 0.11 
Government education/awareness initiatives to promote e-prescribing 
 
0.734 
   
E-prescribing software vendors promotion of e-prescribing 0.694 
Medicare’s monetary incentives for e-prescribing adoption 0.689 
Medicare’s monetary disincentives for e-prescribing adoption 0.626 
Ongoing policy changes related to e-prescribing 0.523 
Availability of national standards related to e-prescribing 0.522 
Availability of appropriate vendors for my practice 0.502 
The lack of adoption of e-prescribing by other physicians 0.484 
 Component 5 – Patient Factors 4 
 
0.905 5.00 ± 8.20 1.25 
Effect of e-prescribing on the physician-patient conversation during the visit 
 
0.733 
   
Effect of patients’ perceptions on my use of e-prescribing technology 0.722 
Effect of e-prescribing on patients’ likelihood to pick up their medication from the pharmacy 0.671 
Ability to maintain patient confidentiality when e-prescribing 0.627 
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Table 12 (cont): Principal Component Analysis and Reliability Results 
Items 
Number 
of Items 
Standardized 
Coefficients 
  
  
  
  
  
  
  
  
  
  
  
  
   
 
Cronbach’s 
Alpha 
Mean ± SD 
Per-
Item 
Mean 
Component 6 – Post-Implementation Factors 4 
 
0.842 4.36 ± 8.83 1.09 
Comfort level with writing electronic prescriptions 
 
0.748 
   
Time required for an electronic prescription to reach the pharmacy 0.618 
Effect on productivity after e-prescribing implementation 0.589 
Time taken to complete an electronic prescription 0.524 
Component 7 – Cost Factors 3 
 
0.916 -2.94 ± 7.20 -0.98 
Financial cost of updating/upgrading the e-prescribing system 
 
0.796 
   
Initial cost of implementation 0.765 
Return on investment related to e-prescribing 0.729 
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Objectives 1 and 2 
 The first objective of this study was to determine the factors that physicians find 
encouraging and discouraging about e-prescribing. Overall, respondents reported pre-
implementation factors, and cost factors to be slightly discouraging.  Respondents reported 
technology factors, software features, and patient factors to be encouraging, with software 
features being the most encouraging to respondents.  Results from external influences and post-
implementation factors were mixed with minor encouragement, depending on the group of 
respondents (Table 14). 
 The second objective of this study was to compare the factors that physicians find 
encouraging and discouraging about e-prescribing based on their specific e-prescribing adoption 
status.  MANOVA was conducted to accomplish this objective of this study.  Significant 
differences in perceptions of the e-prescribing factors were identified among the physician 
groups for all factors except “features” (p < .05) (Table 13). 
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Table 13:  MANOVA Results for Objective 2 
  
Sum of 
Squares 
df Mean Square F Sig. 
Pre-
Implementation 
Between Groups 152.829 4 38.207 8.925 .000 
Within Groups 1712.421 400 4.281   
Total 1865.250 404    
Technology 
Between Groups 105.490 4 26.372 7.769 .000 
Within Groups 1357.781 400 3.394   
Total 1463.271 404    
Features 
Between Groups 23.992 4 5.998 1.985 .096 
Within Groups 1208.514 400 3.021   
Total 1232.506 404    
External 
Influence 
Between Groups 40.346 4 10.086 3.511 .008 
Within Groups 1149.006 400 2.873   
Total 1189.352 404    
Patients 
Between Groups 90.924 4 22.731 5.655 .000 
Within Groups 1607.826 400 4.020   
Total 1698.750 404    
Post-
Implementation 
Between Groups 142.931 4 35.733 7.835 .000 
Within Groups 1824.172 400 4.560   
Total 1967.103 404    
Cost 
Between Groups 112.963 4 28.241 5.098 .001 
Within Groups 2215.670 400 5.539   
Total 2328.633 404    
Overall 
Between Groups 77.443 4 19.361 8.308 .000 
Within Groups 932.169 400 2.330   
Total 1009.612 404    
 
To more specifically determine which physician groups differed from others with regard 
to their perceptions of each factor, post-hoc tests were conducted using Tukey’s post-hoc tests 
(Table 14).   
For pre-implementation factors, technology factors, post-implementation factors, cost 
factors and overall factors, means are significantly different between group 1 (physicians who 
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adopted e-prescribing more than six months ago) and group 4 (physicians who are planning to 
adopt e-prescribing within six months) at alpha ≤ 0.05.  In addition, means were significantly 
different between group 1 (physicians who adopted e-prescribing more than six months ago) and 
group 5 (physicians who have considered but have no intention of adopting e-prescribing in the 
near future) for all factors (pre-implementation factors, technology factors, external influence 
factors, patient factors, post-implementation factors, cost factors, and overall factors) except for 
features at alpha ≤ 0.05.   
For pre-implementation factors, physicians who have been using e-prescribing 
technology for more than six months are less discouraged by the e-prescribing pre-
implementation factors than physicians who are planning to adopt e-prescribing technology in 
the next six months (p < 0.005).  Similarly, physicians who have been using e-prescribing 
technology for more than six months are less discouraged by the e-prescribing pre-
implementation factors than physicians who have no intention of adopting e-prescribing in the 
near future (p<0.005). 
For technology factors, physicians who have been using e-prescribing technology for 
more than six months are more encouraged by technology factors than physicians who are 
planning to adopt e-prescribing technology in the next six months (p = 0.026).  Similarly, 
physicians who have been using e-prescribing technology for more than six months are more 
encouraged about technology factors than physicians who have no intention of adopting e-
prescribing in the near future (p < 0.005). 
For external influence, physicians who have been using e-prescribing technology for 
more than six months are encouraged by external influence factors and physicians who have no 
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intention of adopting e-prescribing in the near future are discouraged by external influences 
factors (p = 0.003). 
For patient factors, physicians who have been using e-prescribing technology for more 
than six months are more encouraged than physicians who have no intention of adopting e-
prescribing in the near future (p < 0.005). 
For post-implementation factors, physicians who have been using e-prescribing 
technology for more than six months are more encouraged regarding post-implementation factors 
than physicians who are planning to adopt e-prescribing technology in the next six months (p = 
0.012).  Interestingly, physicians who have been using e-prescribing technology for more than 
six months are encouraged by post-implementation factors and physicians who have no intention 
of adopting e-prescribing in the near future are discouraged by post-implementation factors (p < 
0.005). 
For cost factors, physicians who have been using e-prescribing technology for more than 
six months are less discouraged by cost factors than physicians who are planning to adopt e-
prescribing technology in the next six months (p = 0.009).  Similarly, physicians who have been 
using e-prescribing technology for more than six months are less discouraged by cost factors 
than physicians who have no intention of adopting e-prescribing in the near future (p = 0.004). 
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Table 14: Means of Encouraging and Discouraging Factors about Electronic Prescribing Based on Respondents 
Current E-Prescribing Status 
 
 a
Measured on a 11-point bipolar scale where -5 = “greatly discourages me”, +5 = “greatly encourages me” and 0 = “does not affect me”. 
 
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Pre-
Implementation 
-0.24 1.87 -1.24 2.08 -0.67 2.98 -1.45 2.12 -1.80 2.12 -0.72 2.15 
Technology 1.68 1.73 0.96 1.65 0.93 2.22 0.90 1.94 0.27 2.04 1.27 1.90 
Features 2.39 1.74 1.70 1.48 2.59 1.73 2.61 1.67 1.99 1.91 2.35 1.75 
External 
Influence 
0.30 1.56 0.22 1.44 0.17 2.39 -0.10 1.74 -0.64 1.78 0.11 1.72 
Patients 1.63 1.97 0.74 2.34 1.11 2.09 0.86 1.87 0.35 2.09 1.25 2.05 
Post-
Implementation 
1.57 2.13 0.73 1.78 0.68 2.34 0.59 2.06 -0.03 2.24 1.09 2.21 
Cost -0.61 2.22 -1.09 2.04 -0.69 3.00 -1.72 2.36 -1.90 2.57 -0.98 2.40 
Overall 0.96 1.42 0.29 1.41 0.59 1.89 0.24 1.56 -0.25 1.74 0.62 1.58 
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Objective 3  
 The third objective of this study was to determine which demographic factors are 
significant predictors of physicians’ perceptions of encouraging and discouraging factors for e-
prescribing.  Physicians’ 12 demographics characteristics (gender, age, years in practice, years 
left to practice, practice size, number of nurses, number of outpatients seen per week, number of 
outpatient prescription written per week, rural/urban status, geographical location, practice type, 
and practice setting) and physicians’ perceptions of encouraging and discouraging factors for e-
prescribing (on the overall scale) were tested using a multiple linear regression with alpha = 0.05 
(Table 15).  Categorical variables such as practice type (PT), practice setting (PS), and 
geographical location (GL) were entered using reference cell coding for linear regression.  
Results of the analysis suggest that all the variables taken together explain a significant amount 
of variation in overall perceptions of encouraging and discouraging factors for e-prescribing (p = 
0.025). 
Table 15: Overall Regression Results (Objective 3)  
ANOVA
b
 
Model Sum of 
Squares 
Df Mean 
Square 
F Sig. 
1 Regression 86.715 21 4.129 1.725 .025
a
 
Residual 912.170 381 2.394   
Total 998.885 402    
a. Predictors: (Constant), GL_3, PT_1, No of Nurses, PS_3, PS_7, ZIPCODE, PS_6, 
PS_5, No of 50utpatients seen per week, PS_4, Age, Gender, GL_1, PT_2, PS_1, 
PS_2, No of outpatients RX per week , GL_2, More years to practice medicine, Post 
Residency Years, FTE Physicians 
b. Dependent Variable: overall factors 
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 Based on these results, among all demographic variables entered, only age and physicians 
practicing at an academic/university health center significantly predict physicians’ perceptions of 
encouraging and discouraging factors for e-prescribing, given that other demographic variables 
are already present in the model (Table 16).  Additionally, the beta coefficient for age (β = -
0.052) shows that with increasing age physicians are more likely to be discouraged by overall e-
prescribing factors.  Moreover, physicians practicing in an academic/university environment (β = 
1.21) are more likely to view e-prescribing factors as encouraging. 
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Table 16: Multiple Linear Regression results 
Coefficients
a
 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 (Constant) 2.579 1.100 
 
2.344 0.020 
Gender 0.068 0.195 0.018 0.348 0.728 
Age -0.052 0.021 -0.271 -2.432 0.015 
Years in practice 0.032 0.020 0.167 1.620 0.106 
Years left in practice 0.008 0.014 0.041 0.554 0.580 
Practice size 0.000 0.003 -0.006 -0.050 0.960 
Number of nurses 0.002 0.003 0.081 0.684 0.494 
No of outpatients seen per 
week 
-0.001 0.001 -0.055 -1.001 0.317 
No of outpatients RX per 
week  
-0.001 0.001 -0.059 -1.059 0.290 
Zip code 0.264 0.219 0.062 1.205 0.229 
PT_1 (Internal Medicine) 0.067 0.168 0.021 0.400 0.689 
PT_2 (Other) -0.019 0.335 -0.003 -0.056 0.955 
PS_1 (Hospital owned-
office based) 
-0.126 0.208 -0.032 -0.605 0.545 
PS_2 (Hospital based) 0.096 0.529 0.010 0.182 0.855 
PS_3 
(Outpatients/community) 
0.101 0.603 0.008 0.168 0.867 
PS_4 (Group/Staff HMO) 0.284 0.716 0.022 0.397 0.692 
PS_5 
(Academic/University 
health center) 
1.208 0.473 0.130 2.552 0.011 
PS_6 (County health 
department) 
1.642 1.590 0.052 1.033 0.302 
PS_7 (community health 
center) 
0.463 0.712 0.033 0.650 0.516 
GL_1(Midwest) -0.406 0.220 -0.114 -1.850 0.065 
GL_2 (South) -0.355 0.210 -0.106 -1.688 0.092 
GL_3 (West) -0.288 0.260 -0.066 -1.108 0.269 
a. Dependent Variable: Overall_Factors 
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V. DISCUSSION 
Discussion of Study Results and Implications for E-Prescribing Vendors 
While more physicians are e-prescribing every day, the IOM’s goal that all prescriptions 
be electronically routed by 2010 clearly has not been met.  Therefore, it behooves stakeholders 
of e-prescribing, particularly e-prescribing software vendors, to identify and address the 
challenges that physicians face with regard to e-prescribing.  Examining the e-prescribing 
literature thus far, demographic factors related to physician adoption of e-prescribing (Kralewski 
et al., 2008; Pizzi et al., 2005), physician beliefs about e-prescribing (Pizzi et al., 2005), and 
general reports of barriers and concerns by physicians have been reported in the literature 
(American Medical Association, 2008; Pizzi et al., 2005).  However, this data may not be 
specific enough to help e-prescribing vendors target the challenges faced by physicians.  This 
study sought to provide a quantitative examination of factors that physicians find encouraging 
and discouraging about e-prescribing and how those perceptions vary among different types of 
physicians and their specific state of e-prescribing.  Discerning the encouraging and discouraging 
factors that physicians perceive is important to prioritize initiatives to more adequately facilitate 
the adoption of e-prescribing.   
Before examining factors that e-prescribers, future e-prescribers, and non-e-prescribers 
find encouraging and discouraging, it was thought that some e-prescribers may actually quit e-
prescribing (relapse) for a variety of reasons.  As of yet, this idea has not emerged from the e-
prescribing literature.  Results of this study indicated that 98 (22.1%) respondents started but 
then stopped using e-prescribing in the past regardless of their current e-prescribing status.  
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Reasons provided by respondents for discontinuing the use of e-prescribing in the past were 
hardware problems (12.4%), software problems (34.0%), workflow problems (27.9%), and other 
problems (25.5%) such as cost issues, time consumption, lack of pharmacy connections, etc.  
Some respondents who indicated the “other” category noted a change in job or practice as a 
reason that they stopped e-prescribing, not necessarily a problem with e-prescribing, itself.  
These results indicate that many of the reasons for discontinuing the use of e-prescribing were 
due to technology and other problems.  E-prescribing vendors should be cognizant of the 
potential for e-prescribing attrition and make efforts to enhance retention through support 
initiatives.  And, perhaps they already have, because among respondents who discontinued e-
prescribing, approximately 54% of them are currently using e-prescribing and about 26% of 
them are again planning to adopt e-prescribing technology in the next six months. 
 Results of this study also indicate that e-prescribing respondents, on average, required 
four months for medical practices and staff to adopt and transition to electronic prescribing to the 
point of being fully functional.  This finding is especially important to vendors and future e-
prescribers.  Vendor companies can use this information to market their products in the basis of 
time and in addition, they can provide more technical and workflow support to the future e-
prescribing adopters so that the transition and adoption is smooth.   
When e-prescribers were asked to indicate their preference for e-prescribing or traditional 
prescribing, over four-fifths of the e-prescribers indicated that they do, indeed, prefer electronic 
prescribing.  However, a little over half of the responding e-prescribers (53.7%) indicated they 
have experienced problems with their electronic prescribing software.  For the respondents who 
indicated software problems, the types of problems encountered is summarized in Table 17 
below.  
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Table 17: Types of Problems Encountered by E-Prescribers 
Very slow/too many clicks 
Prescription does not reach pharmacy/pharmacy connectivity 
Formulary is not updated 
Many safety alerts 
Productivity loss 
Workflow problems 
Frequent updates and maintenance required 
System freezes  
Wrong information in the medication list 
No generic substitution options available  
Cannot prescribe controlled substances 
 
E-prescribing vendors should pay close attention to the problems encountered by 
physicians because that is very important not only to decrease the attrition rate among current e-
prescribers, but also to increase their satisfaction level related to the technology.   We can see 
one specific trend in these problems, technology.  Nevertheless, most of the e-prescribers (83%) 
indicated satisfaction with the e-prescribing system they are currently using.  Lastly, consistent 
with other studies (Fischer et al., 2007), most of our study respondents reported problems related 
to prescribing controlled substances.  However, on June 1, 2010, the Drug Enforcement Agency 
(DEA) issued its interim final rule allowing for the paperless prescribing of controlled substances 
(Federal Register, 2010).  Therefore, physicians can now e-prescribe controlled substances in 
some states.  This may still be a problem at the state level because of the potential for the rules 
that do not match system capabilities.   
Coming back to factors that e-prescribers, future e-prescribers, and non-e-prescribers find 
encouraging and discouraging about e-prescribing, the first objective of this study was to 
determine the factors that physicians find encouraging and discouraging about e-prescribing.  
Overall, respondents, regardless of adoption status, reported pre-implementation factors and cost 
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factors to be slightly discouraging.  This is consistent with other studies conducted in this area 
(Pizzi et al., 2005, Halamka et al., 2006, Smith, 2006).  Cost factors not only include initial cost 
of implementation, but also future upgrading costs and return on investment.  It is not likely that 
physicians may ever find the cost of e-prescribing encouraging, but vendors may want to focus 
on emphasizing the value of their products and value of e-prescribing in general, to lessen the 
“pain” associated with the cost of e-prescribing. 
Respondents found technology factors, software features, and patient factors to be 
encouraging, with software features being the most encouraging.  Attitudes regarding external 
influences and post-implementation factors were mixed, depending on the category of 
respondents.  It should be noted that external influences consisted of some of the policy and 
government/vendor initiative items (Table 12).  As might be expected, physicians who have 
already adopted the e-prescribing technology or are planning to adopt in the near future were 
neutral to encouraged by external influences.  On the contrary, the physicians who are not 
planning to adopt e-prescribing are actually discouraged by external influences.  Interestingly, all 
respondents found electronic prescribing software features to be encouraging, and, in fact, the 
most encouraging of all the factors.  This may suggest that electronic prescribing vendor 
companies are meeting or exceeding the expectations of prescribers when it comes to the features 
contained in the packages.  Vendors can boost promotion of e-prescribing technology by 
emphasizing the value of software features.   
The second objective of this study was to compare the factors that physicians find 
encouraging and discouraging based on their specific e-prescribing adoption status.  The results 
of this analysis suggest that those respondents who have considered e-prescribing but have no 
intention to adopt it and those respondents who are in the process of adopting e-prescribing in the 
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next six months are, in general, significantly more discouraged about e-prescribing factors than 
those who have adopted e-prescribing greater than six months ago.  In fact, anecdotally, it 
appears that there is a linear relationship between stage of e-prescribing adoption and the 
perception of how encouraging or discouraging physicians perceive e-prescribing factors.  While 
future research may be needed to explore this further, these findings may suggest that the “fear 
of the unknown” may play a role in prescribers’ perceptions of electronic prescribing and 
associated software.   Then, upon adoption and “getting used to” e-prescribing, they may find 
that “e-prescribing isn’t so bad, after all.”  If confirmed, e-prescribing vendors should address the 
“unknown” when calling on prescribers by alleviating anxiety, fears, and concerns.  Along with 
this component of future research, it may also be helpful in future research to capture the point at 
which physicians “relapse” from e-prescribing.  If it is found that physicians relapse soon after 
adoption, it may help confirm the findings described here.  
Results of this study suggest that physicians who have used e-prescribing technology for 
more than six months are less discouraged by pre-implementation factors compared to 
physicians who are planning to adopt e-prescribing in the next six months and physicians who 
have considered but are not planning to adopt e-prescribing system.  This finding suggests that 
physicians who have already undergone the transitional phase become somewhat comfortable 
handling the e-prescribing system and are more accustomed to the workflow redesign requires 
with the adoption od e-prescribing compared to physicians who have yet to adopt or who are in 
the process of adoption e-prescribing.  This should not be surprising.  However, physicians who 
have undergone the transitional phase still find pre-implementation factors somewhat 
discouraging.  Vendors may want to provide additional technical support during the 
implementation phase to adopters.  Additionally, vendors should develop interventions to reduce 
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the anxiety associated with some of the pre-implementation factors among future e-prescribers 
and thus increasing the adoption rate among non-e-prescribing physicians. 
 Results of this study also suggest that physicians who are using e-prescribing technology 
for more than six months are more encouraged by the technology factors compared to 
physicians who are planning to adopt it in the next six months and physicians who have 
considered but not planning to adopt e-prescribing technology.  These results suggest that after 
gaining some experience, uncertainty with regard to technology such as the “number of 
pharmacies participating in e-prescribing” and “effect on overall prescribing error rates due to e-
prescribing” is reduced.  One of the reasons that physicians who are not e-prescribing or are in 
the process of implementing e-prescribing are less encouraged by technology can possibly be 
attributed to apprehension of the new technology, in general.  Vendors can mitigate this 
apprehension by making more transparent details related to technology can consider providing 
more information regarding the technology and its capabilities in order to reduce anxiety and 
improve confidence among future e-prescribers.   
Interestingly, regardless of adoption status, all physicians were quite encouraged by 
software features, and there were no significant differences between adoption categories on this 
factor.  Because this study demonstrates that even non-e-prescribers are generally encouraged by 
software features, future studies should explore how the adoption rate of e-prescribing can be 
enhanced by emphasizing software features.  In addition, vendors may also want to place 
increased emphasis on their software features to encourage adoption and enhance their own 
competitiveness. 
This study also indicates that that current e-prescribers, future e-prescribers and non-e-
prescribers are minimally affected by external influences such as Medicare’s monetary 
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incentives and disincentives for e-prescribing adoption.  A future longitudinal study should be 
conducted to determine if there are changes in adoption patterns before and after 2012.  Based on 
MIPPA, physicians who successfully adopt e-prescribing by 2011 will receive annually 
decreasing reimbursement incentives until 2013 and those who fail to adopt by 2012 will be 
penalized by reimbursement disincentives until their adoption (Medicare Improvements for 
Patients and Providers Act of 2008).  It is possible that non-e-prescribers are tolerant of future 
Medicare disincentives but intolerant to the additional costs associated with e-prescribing 
adoption.  In other words, costs related to technology for implementation and upgrade may 
outweigh the Medicare disincentives that physicians will experience in the future.  Or, Non-e-
prescribers may not see many Medicare patients anyway, which may mitigate the impact of 
reimburse disincentives felt by these physicians. 
Physicians who have used e-prescribing technology for more than six months are more 
encouraged by patient factors compared to physicians who have no intention of adopting e-
prescribing in the near future.  This finding suggests that adopters as well as non-adopters are 
encouraged by patient factors, however, with experience; physicians become more encouraged 
by patient factors which include like “effect of e-prescribing on the physician-patient 
conversation during the visit”, “effect of patients’ perceptions on my use of e-prescribing 
technology”, etc.  Pizzi et al. (2005) reported that non-e-prescribers are more likely to report that 
e-prescribing technology has negative impact on “interference with physician-patient 
relationships”, “fear of patients satisfaction with electronic prescribing”, “patients’ 
confidentiality concerns”, and so on.   Interestingly, in this study, it was found that non-e-
prescribers, although less so than e-prescribers, are generally encouraged by patient factors and 
feel that e-prescribing does not necessarily have a negative impact on the physician-patient 
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relationship. It should be noted, however, that Pizzi et al. (2005) conducted their study in 2003, 
while this study was conducted in 2010.  Since 2003, e-prescribing technology has undergone 
many changes, some of which make e-prescribing perhaps less intrusive on the patient-physician 
relationship.  Also, as e-prescribing, electronic health records and electronic medical records 
have infiltrated the health care environment, physicians may be achieving a new “normal” with 
regard to integration of technology into their practices. 
For post-implementation factors, physicians who have been using e-prescribing 
technology for more than six months are more encouraged by post-implementation factors 
compared to physicians who are planning to adopt e-prescribing technology in the next six 
months.  This finding suggests that experience with e-prescribing technology does matter.  
Because once physicians gain experience with the technology, they are not greatly affected by 
post-implementation factors.  This should not come as a surprising finding.  Also not 
surprisingly, physicians who have no intention of adopting e-prescribing in the near future are 
discouraged by post-implementation factors compared to physician who have been using e-
prescribing for over six months.  These results suggest that future research should focus on 
interventions to encourage non-e-prescribers.  Perhaps vendors can provide free trials of e-
prescribing software for three to six months to help reduce the anxiety of non e-prescribers, 
making them more motivated to adoption e-prescribing and less discouraged by post-
implementation factors. 
Physicians who have been using e-prescribing technology for more than six months are 
less discouraged by cost factors compared to physicians who are planning to adopt e-prescribing 
technology in the next six months.  Similarly, physicians who have been using e-prescribing 
technology for more than six months are less discouraged by cost factors compared to physicians 
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who have no intention of adopting e-prescribing in the near future.  Overall, physicians were 
discouraged by cost factors.  This result is consistent with other studies in this area (Pizzi et al., 
2005, Halamka et al., 2006, Smith, 2006).  Apart from improving quality and saving time, some 
of the primary benefits of e-prescribing are reducing costs mainly to patients and payers 
(Papshev et al., 2001).  However, physicians perceive higher financial burden with little direct 
benefit compared to costs and benefits perceived by patients, payers, and pharmacists.  To a 
certain degree, government and state policies like MIPPA disincentives/incentives have helped 
increase the adoption rate among physicians working at large clinics and health centers 
(Surescripts, 2009); however, the policies may not help tremendously in reducing the financial 
burden among primary care physicians.  Nevertheless, the findings of this study also suggest e-
prescribers are less discouraged by cost factors compared to non-e-prescribers.  Again, providing 
free e-prescribing software or a free trial for a few months can help alleviate some of the 
financial burden among future e-prescribers. 
The third objective of this study was to determine which demographic factors were 
significant predictors of physicians’ perceptions about factors that may be encouraging or 
discouraging about e-prescribing.  Findings of this study suggest that older physicians perceive 
e-prescribing factors, in general, to be more discouraging relative to younger physicians.  
Anecdotally, this is not surprising because we know that it is more difficult to adapt new 
technology with age.  Moreover, these results are consistent with previous studies which have 
suggested that physician age is a significant predictor of e-prescribing adoption among 
physicians (e.g., Fisher et al., 2007).  An ANOVA conducted with adoption status as the 
independent variable and age as the dependent variable somewhat supports the regression results 
of this study.  It was found that physicians who are in the process of adopting e-prescribing in 
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less than a month are younger (48.21 years) compared to physicians who are not planning to 
adopt e-prescribing (54.95 years) (F = 2.95, p = 0.012).   
  Regression results also suggest that physicians working at academic/university settings 
perceive e-prescribing as more encouraging than physicians working in other settings.  Most 
study respondents working at academic/university setting indicated to have already been using e-
prescribing technology for more than 6 months.  Anecdotally this is not surprising as medical 
practice in academic and university settings may often be more progressive than medical practice 
in other settings.  However, caution should be taken when interpreting these findings, as only 
twelve respondents reported working in the academic/university setting. 
Additional Directions for Future Research 
 
In addition to the future research ideas proposed thus far, future research should also 
evaluate the encouraging and discouraging factors of e-prescribing among physicians practicing 
in specialty areas such as cardiology.  To determine if similar perceptions are shared by 
specialists.  While the intent of this study was to target those physicians who most commonly 
write outpatient prescriptions (PCPs), a similar study in physicians’ specialists is certainly 
warranted.   
According to a 2009 report by Surescripts, many payers are not able to provide access to 
prescription benefit and history information to e-prescribing vendors.  There are some states 
(e.g., Mississippi and North Dakota) which are clearly lagging behind in receiving this type of 
information.  In these states, Surescripts is able to provide only 0-40% of prescription benefit and 
history information to physicians because this is all they receive from payers.  Therefore, future 
research should study factors affecting payers’ lack of provision of information and develop 
interventions to encourage payers to provide this information.  This approach will also help 
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increase the adoption because some physicians still believe that the payers’ connectivity is still 
an issue (eHealth Initiative, 2008).  This phenomenon may be related to other findings by 
Surescripts suggesting that there is regional variation in adoption rates and e-prescribing 
utilization in similar states.  A more in-depth study to explore regional variation in e-prescribing 
adoption is warranted.   
Most of the scale items studied in this study was obtained from the e-prescribing 
literature and resultant subscales demonstrated acceptable reliabilities with Cronbach’s alpha 
ranging from .842 to .945, with the overall scale being .967.  However, future study should test 
these scales again in different physician groups to validate the reliability and validity of the scale 
implemented in this study. 
As it was stated earlier, it would be worth conducting a pre-post longitudinal study 
among physicians before and after 2012.  According to MIPPA, physicians who successfully 
adopt e-prescribing by 2011 will receive annually decreasing incentives until 2013 and those 
who fail to adopt by 2012 will be penalized until adoption.  Although it might be assumed that 
physicians will be compelled to adopt e-prescribing technology to avoid disincentives from 
Medicare, national adoption rates of e-prescribing may suggest otherwise.  Therefore, the results 
of a longitudinal study may be very intriguing. 
Finally, it was proposed in this discussion that vendors provide a free trial of e-
prescribing software or a few months of initial free e-prescribing software to mitigate the 
negative impact of financial burden on e-prescribing adoption.  Testing the effect of this 
intervention on intention to adopt e-prescribing or actual adoption of e-prescribing may be a 
study welcomed by vendors who already provide these incentives, or are considering doing so. 
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Limitations 
 
 A physician panel was used to collect data for this study and a monetary honorarium was 
not provided to participants (although participants did receive a final report of the findings).  
While it was made clear in the recruitment letter that this study was being conducted for 
academic purposes only and that the study was equally applicable to prescribers and non-e-
prescribers, there is still a strong likelihood self-selection bias occurring in this study.  This may 
explain the distribution of e-prescribers and non-e-prescribers in this study, which is certainly not 
representative of national adoption rates most commonly presented by Surescripts (Surescripts 
Report, 2009).  Thus, it may have been those physicians who were most engaged in e-prescribing 
(and our final report) who ultimately participated in the study.  As a related limitation, there were 
clearly unequal group sizes among the five stages of e-prescribing.  However, given the study 
did not employ a factorial design, this limitation was not determined to be overly problematic. 
 Generalizability of this study is limited, in part, because only PCPs (particularly 
family/general practice and internal medicine) were studied and in part because of the strong 
potential for self-selection bias.  Therefore, the results of this study cannot be generalized to all 
the physicians practicing in different specialty areas. 
Finally, the nature of this study design is cross-sectional. Therefore, it implies no causal 
relationships among variables.  Future studies should employ alternative designs such as 
longitudinal data collection to more fully understand causal relationships among variables. 
Conclusions  
 
 The national adoption rate of e-prescribing is clearly growing among physicians however, 
not at a rate that meets IOM’s goals that all prescriptions be routed electronically by 2010.  
Overall, respondents reported pre-implementation factors and cost factors to be slightly 
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discouraging.  Respondents reported technology factors, software features, and patient factors to 
be encouraging, with software features being the most encouraging to respondents.  External 
influences and post-implementation factors were slightly encouraging and discouraging, 
depending on the group of respondents.  One of the most significant results of this study suggests 
that those respondents who have considered e-prescribing but have not intention to adopt it and 
those respondents who are in the process of adopting e-prescribing in the next six months are, in 
general, significantly more discouraged about e-prescribing factors than those who have adopted 
e-prescribing greater than six months ago.  Finally, age and practice type were found to most 
significantly predict physicians’ perceptions of encouraging and discouraging factors for e-
prescribing. 
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Appendix A:  Cover Letter 
 
This is where the JRAMedNet.com the power to do more banner in HTML will show up 
 
JRAMedNet with University of Mississippi online survey – Opinions of Electronic Prescribing 
 
Dr.  <<MERGE NAME>> 
 
Reckner Healthcare, on behalf of The University of Mississippi School of Pharmacy graduate 
student Krutika Jariwala, would like to invite you to participate in a research study regarding 
your opinions on electronic prescribing.  This research project is a part of Ms Jariwala’s thesis 
requirement and your response is not only important for the identifying the key issues for 
technology adoption but also valuable in order to complete her Master’s degree.  This survey is 
being fielded for academic inquiry only, and not commercial purposes.  A summary of results 
will be made available upon completion of the study to those interested respondents.  This survey 
should take no more than 10-15 minutes to complete. 
 
No identifying information will be collected from this Internet survey.  As a result, your response 
will remain anonymous.  This study has been reviewed by The University of Mississippi’s 
Institutional Review Board (IRB).  The IRB has determined that this study fulfills the human 
research subject protections obligations required by state and federal law and University policies.  
If you have any questions, concerns, or reports regarding your rights as a participant of research, 
please contact the IRB at (662) 915-7482. 
 
Please attempt to complete the survey in one sitting.  If you choose, you may suspend the survey 
and return later, but we cannot guarantee the study will be open upon your resume.   
 
Please click on the following link to access the survey:  
www.JRAMedNet.com 
 
If you are having trouble logging on with the link above, please copy and paste the link below 
into your web browser: 
http://www.jramednet.com/login.aspx?ID=XXXXXXX 
 
If you have difficulty logging onto the survey link, please email webhelp@reckner.com and 
reference study #1248. 
 
We ask that you please take your time to read and answer each question appropriately.  We have 
pretested and timed our surveys to ensure that our client is receiving accurate and thoughtful 
information from respondents.  We do appreciate your careful attention to each question we ask. 
 
We value your participation in this research study as it will allow us to better understand the 
factors that influence electronic prescribing adoption, and we greatly encourage you to 
participate.  If you have questions about this study, please contact Krutika Jariwala directly by 
office phone at 662-915-5948, or by email at kjariwal@olemiss.edu. Thank you very much for 
assisting us with this very important research project. 
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To further help target our survey invitations Reckner Healthcare, through JRAMedNet.com, has 
made available respondent profile(s) that are appropriate for you.  Please take a moment to 
update your profile(s) and browse our new platform, from which you may track payments, 
update contact information, etc. 
 
To view our privacy statement please click here: http://www.reckner.com/faq/privglob.htm 
 
Thank you,  
 
Anna Cunningham, Project Manager, Reckner Healthcare 
 
In cooperation with: 
 
Krutika Jariwala 
Graduate Student 
Dept. of Pharmacy Administration 
University of Mississippi 
662-801-7111 
 
Erin Holmes, PharmD, PhD 
Assistant Professor of Pharmacy Administration 
Research Assistant Professor, Research Institute of Pharmaceutical Sciences 
University of Mississippi School of Pharmacy  
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Appendix B:  Questionnaire  
 
1. Are you: 
 Male 
 Female 
 
 
2. What is your age?  
   years 
 
3. For how many years have you been practicing medicine (post-residency)?  
    years 
 
 
4. For approximately how many MORE years do you plan to practice medicine? 
    years 
 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
 
 
5. Which best describes your practice type? (Please select one, only) 
 Family/general medicine 
 Internal medicine 
 Pediatrics 
 Obstetrics/gynecology 
 Other    
 
 
6. Which BEST describes your practice setting? (Please select one, only) 
 Private practice 
 Hospital-owned, office-based 
 Hospital-based 
 Outpatient public/community clinic  
 Group or staff model HMO  
 Academic health center or university  
 County health department
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 Community health center 
 Other            
 
7. In which state is your primary practice located? 
(Insert standard state list drop-down menu) 
 
 
 
8. Please indicate the zip code in which your primary practice setting is located. 
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9. How many full time equivalent (FTE) physicians are in your practice?  (40 hours = 1 FTE) 
   physicians 
 
 
10. How many nurses are in your practice? 
   nurses 
 
 
11. Approximately how many patients do you see in one week?  
   patients 
 
 
12. Approximately how many outpatient prescriptions do you write in one week? 
   prescriptions 
 
 
13. What percentage of your patient population is covered by: 
The Original Medicare Plan (fee-for-service)    % 
Medicare Advantage       % 
Other         % 
 
 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
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The term ELECTRONIC PRESCRIBING is defined by Centers for Medicare & Medicaid 
Services (CMS) as: 
 “The transmission, using electronic media, of prescription or prescription-related information 
between a prescriber, dispenser, pharmacy benefit manager, or health plan, either directly or 
through an intermediary, including an e-prescribing network.” 
“E-prescribing includes, but is not limited to, two-way transmissions between the point of care 
and the dispenser.” 
 
14. Regardless of your current use of e-prescribing, have you ever started and stopped using e-
prescribing in the past? 
 Yes  Go to Q15 
 No  Go to Q16 
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15. What is your primary reason/s for discontinuing use of electronic prescribing technology in 
the past? (Select all that apply) 
 Software problems 
 Hardware problems 
 Workflow problems 
 Other                                             
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16. What is the CURRENT STATUS of electronic prescribing in your practice? (Please select 
one, only) 
 
 My practice has been using an electronic prescribing system for outpatient prescriptions 
for more than 6 months  Go to Q17 
 
 My practice has been using an electronic prescribing system for outpatient prescriptions 
for less than 6 months  Go to Q17 
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 My practice is currently in the process of implementing or planning to implement it in 
less than 30 days      Go to Q28 
 
 My practice is not planning to implement it in the next 30 days, but is planning to 
implement it in the next 6 months"     
     Go to Q28 
 
 My practice has considered using electronic prescribing and has no intention of adopting 
in the next 6 months  Go to Q28 
 
 My practice has not considered using electronic prescribing and has no intention of 
adopting it in the next 6 months  TERMINATE.  Thank you for your willingness to 
participate in our survey.  However, it is only relevant to physicians who have considered 
using electronic prescribing. 
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17. How satisfied you are with your current electronic prescribing system?  
 Completely satisfied 
 Mostly satisfied 
 Slightly satisfied 
 Neither satisfied nor dissatisfied 
 Slightly dissatisfied 
 Mostly dissatisfied 
 Completely dissatisfied 
 
 
18. Approximately, how many months did it take your practice to adopt and transition to 
electronic prescribing to the point of being fully functional?  
   months 
 
 
19. Have you received any free e-prescribing software? 
  Yes  Go to Q20   
  No   Go to Q21 
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20. Please specify the source (e.g. vendor, government, etc.) of your free e-prescribing software: 
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21. Which of the following do you have? (Select all that apply) 
   Standalone e-prescribing software 
  Integrated e-prescribing software with Electronic Health Records 
  Integrated e-prescribing software with Electronic Medical Records 
 Other                                             
 
 
22. Which type of e-prescribing system are you using at your practice? (Select all that apply) 
 Handheld devices 
 Tablet/laptop personal computers 
 Desktop personal computers 
 Other hardware made available by technology vendors (specify) 
 
 
23. Which is your MOST preferred e-prescribing system? (Please select one, only) 
 Handheld devices 
 Tablet/laptop personal computers 
 Desktop personal computers 
 Insert other hardware made available by technology vendors from Q22  
 
 
24. Which electronic prescribing software/ hardware you are currently using?  
                                             
 
25. Have you encountered any problems with the software you are currently using?  
 Yes  Go to Q26    
 No   Go to Q27 
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26. What problems have you encountered related to the software you are currently using? 
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27. Please specify your primary preference for prescribing: 
 Electronic prescribing  Go to Q30 
 Traditional prescribing  Go to Q30 
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28. Are you aware of the electronic prescribing software/hardware you/your practice is planning 
to adopt in the future? 
 Yes  Go to Q29  
 No   Go to Q30 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
 
 
29. Which electronic prescribing software/ hardware are you/your practice currently using or 
planning to use in the future?  
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30. On a scale from 1 to 5, where 1 = none and 5 = to a great extent, to what extent are/were you 
involved in key decision making for electronic prescribing implementation?  
 
 1            2           3           4           5 
 
31. In your practice, are/were you a key decision maker for electronic prescribing 
implementation? 
 Yes   
 No  
 
 
32. To what extent do you agree/disagree with the decision to adopt/not adopt electronic 
prescribing in your practice? 
 Strongly disagree 
 Disagree 
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 Neither agree nor disagree 
 Agree 
 Strongly agree 
 
33. Please rate your current knowledge about electronic prescribing: 
 Very Poor 
 Poor 
 Average 
 Good 
 Excellent 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
 
 
34. Are you aware of Medicare’s monetary incentives and disincentives (as put into law by the 
American Recovery and Reinvestment Act)? 
 Yes  Go to Q35     
 No   Go to Q36 
 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
 
 
35. On a scale of 1 to 5, where 1 = not at all influential and 5 = very influential, how influential 
were Medicare’s monetary incentives and disincentives (as put into law by the American 
Recovery and Reinvestment Act) in your decision to implement or not implement electronic 
prescribing? 
 
 1            2           3           4           5 
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36. WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 
where -5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, 
please indicate the extent to which the following factors encourage or discourage you about 
electronic prescribing. 
 
FEATURES 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Availability of patient medical history in the electronic 
prescribing system 
                                                                                 
Availability of comprehensive patient insurance eligibility 
information 
                                                                                 
Availability of comprehensive formulary information                                                                                  
Availability of safety drug alerts during e-prescribing                                                                                  
Availability of refill function in the e-prescribing system                                                                                  
Availability of feedback from pharmacy regarding patient 
compliance during refills 
                                                                                 
Availability of prescription receipt confirmation from the 
pharmacy 
                                                                                 
Overall e-prescribing features                                                                                  
 
    Do you have any additional thoughts or comments about e-prescribing features? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -
5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please 
indicate the extent to which the following factors encourage or discourage you about electronic 
prescribing. 
 
COST  
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Initial cost of implementation                                                                                  
Financial cost of updating/upgrading the e-prescribing 
system  
                                                                                 
Return on investment related to e-prescribing                                                                                  
Overall cost factors                                                                                  
 
 
 
     Do you have any additional thoughts or comments about e-prescribing costs? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -5 = 
greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please indicate the extent 
to which the following factors encourage or discourage you about electronic prescribing. 
 
TIME  
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Process of entering existing patient medical history into 
the e-prescribing system during initial implementation 
                                                                                 
Process of entering new patient medical history into the e-
prescribing system when you see a new patient 
                                                                                 
Process of learning and installing a new e-prescribing 
system 
                                                                                 
Process of creating customized templates in an e-
prescribing system 
                                                                                 
Process of selecting an appropriate vendor and system for 
my practice 
                                                                                 
Time taken to complete an electronic prescription                                                                                  
Time required for an electronic prescription to reach the 
pharmacy 
                                                                                 
Overall time factors                                                                                  
 
 
     Do you have any additional thoughts or comments about time factors related to e-prescribing? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -
5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please 
indicate the extent to which the following factors encourage or discourage you about electronic 
prescribing. 
 
 
PERSONNEL 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Training staff/clinicians on a new e-prescribing system                                                                                  
Availability of organizational and staff support during e-
prescribing implementation 
                                                                                 
Overall personnel factors                                                                                  
 
 
Do you have any additional thoughts or comments about personnel factors related to e-
prescribing? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -
5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please 
indicate the extent to which the following factors encourage or discourage you about electronic 
prescribing. 
 
 
WORK FLOW 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Process of infrastructure/workflow redesign while 
implementing e-prescribing 
                                                                                 
Effect on productivity during e-prescribing 
implementation 
                                                                                 
Effect on productivity after e-prescribing implementation                                                                                  
Comfort level with writing electronic prescriptions                                                                                  
Overall workflow factors                                                                                  
 
 
     Do you have any additional thoughts or comments about workflow related to e-prescribing? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -
5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please 
indicate the extent to which the following factors encourage or discourage you about electronic 
prescribing. 
 
EXTERNAL INFLUENCES 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Availability of appropriate vendors for my practice                                                                                  
The lack of adoption of e-prescribing by other physicians                                                                                  
Government education/awareness initiatives to promote e-
prescribing 
                                                                                 
E-prescribing software vendors promotion of e-
prescribing 
                                                                                 
Overall external influences                                                                                  
  
 
     Do you have any additional thoughts or comments about the impact of external influences on 
e-prescribing? 
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 
where -5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, 
please indicate the extent to which the following factors encourage or discourage you about 
electronic prescribing. 
 
 
 
TECHNOLOGY 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Effect on overall prescribing error rates due to e-
prescribing  
                                                                                 
Access of e-prescribing systems from different locations                                                                                  
Availability of Electronic Medical Records/Electronic 
Health Records that incorporate e-prescribing 
                                                                                 
Number of pharmacies participating in e-prescribing                                                                                  
Number of payers connected to e-prescribing technology                                                                                  
Security of electronically sent prescriptions                                                                                  
Quality of currently available e-prescribing software                                                                                  
The need for high speed Internet for the transmission of 
an electronic prescription 
                                                                                 
Availability of software that supports the current 
workflow in my practice 
                                                                                 
Overall technology factors                                                                                  
 
 
     Do you have any additional thoughts or comments about technology factors related to e-
prescribing? 
 
 
 
 
 
 
----------------------------------------------PAGE BREAK-------------------------------------- 
  
  
91 
 
 
WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 
where -5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, 
please indicate the extent to which the following factors encourage or discourage you about 
electronic prescribing. 
PATIENTS 
 
 
 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Ability to maintain patient confidentiality when e-
prescribing 
                                                                                 
Effect of e-prescribing on patients’ likelihood to pick up 
their medication from the pharmacy 
                                                                                 
Effect of e-prescribing on the physician-patient 
conversation during the visit 
                                                                                 
Effect of patients’ perceptions on my use of e-prescribing 
technology 
                                                                                 
Overall patient factors                                                                                  
 
 
    Do you have any additional thoughts or comments about e-prescribing as it relates to patients?    
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WHETHER YOU CURRENTLY E-PRESCRIBE OR NOT, using a scale from -5 to +5 where -
5 = greatly discourages me, +5 = greatly encourages me and 0 = does not affect me, please 
indicate the extent to which the following factors encourage or discourage you about electronic 
prescribing. 
 
 
 
POLICY 
                                                                                               
                                                                                     Greatly                                              Does                                          Greatly 
                                                                                Discourages                                        Not affect                               Encourages 
                                                                                        Me                                                    Me                                                  Me 
  
                                                                                         -5       -4        -3        -2         -1          0         1         2        3         4          5 
Ongoing policy changes related to e-prescribing                                                                                  
Availability of national standards related to e-prescribing                                                                                  
Medicare’s monetary incentives for e-prescribing 
adoption 
                                                                                 
Medicare’s monetary disincentives for e-prescribing 
adoption 
                                                                                 
Overall policy factors                                                                                  
 
 
     Do you have any additional thoughts or comments about policy related to e-prescribing?   
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37. Please indicate your agreement with each of the following statements: 
 
                                                                                               
                                                                                                       Strongly                           Neither Agree                       Strongly 
                                                                                                       Disagree                                 nor                                    Agree 
                                                                                                                                                   Disagree 
I am venturesome and eager to be the first to try new innovations                                                                                  
I am always looking for innovations                                                                                  
I adopt innovations and influence others to do so                                                                                  
My opinion about innovations is respected by peers                                                                                  
I am willing to follow the lead of others in adopting innovations                                                                                  
I go along innovations out of necessity                                                                                  
I need to be convinced of the advantage of innovations by peers                                                                                  
I will adopt innovations but do not attempt to influence others to 
do so 
                                                                                 
I am suspicious of innovations                                                                                  
I am resistant to change                                                                                  
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Thank you very much for taking your valuable time to participate in this survey! 
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Appendix C: Means of Individual Encouraging and Discouraging Items about Electronic Prescribing Based on Respondents 
Current E-Prescribing Status 
Table 18: Means of Pre-implementation Items about Electronic Prescribing Based on Respondents Current E-Prescribing 
Status 
 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Pre-Implementation -0.24 1.87 -1.24 2.08 -0.67 2.98 -1.45 2.12 -1.80 2.12 -0.72 2.15 
Process of learning and 
installing a new e-prescribing 
system 
-0.30 2.20 -1.48 2.35 -0.47 3.23 -1.27 2.63 -1.49 2.41 -0.69 2.45 
Process of entering new patient 
medical history into the e-
prescribing system when you 
see a new patient 
-1.20 2.48 -1.88 2.62 -0.29 3.24 -0.79 2.72 -1.31 2.47 -0.50 2.64 
Process of entering existing 
patient medical history into the 
e-prescribing system during 
initial implementation 
-0.65 2.65 -1.88 2.93 -1.18 3.43 -2.35 2.66 -2.75 2.23 -1.30 2.80 
Process of selecting an 
appropriate vendor and system 
for my practice 
-0.48 2.11 -1.08 2.31 -0.56 2.95 -0.62 2.51 -1.76 2.76 -0.71 2.38 
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Table 18 (cont): Means of Pre-implementation Items about Electronic Prescribing Based on Respondents Current E-
Prescribing Status 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Pre-Implementation -0.24 1.87 -1.24 2.08 -0.67 2.98 -1.45 2.12 -1.80 2.12 -0.72 2.15 
Process of creating customized 
templates in an e-prescribing 
system 
-0.26 2.19 -0.56 2.35 -0.50 3.18 -0.83 2.67 -1.43 2.63 -0.40 2.49 
Training staff/clinicians on a 
new e-prescribing system -0.32 2.26 -1.68 2.34 -0.97 3.27 -1.95 2.25 -1.80 2.58 -0.90 2.50 
Process of 
infrastructure/workflow 
redesign while implementing 
e-prescribing 
-0.22 2.27 -1.20 2.20 -0.71 3.28 -1.75 2.54 -2.02 2.57 -0.79 2.54 
Effect on productivity during 
e-prescribing implementation -0.25 2.56 -0.88 2.68 -0.62 3.56 -1.94 2.64 -1.90 2.79 -0.79 2.79 
Availability of organizational 
and staff support during e-
prescribing implementation 
0.21 2.39 -0.52 2.31 -0.71 3.35 -1.56 2.55 -1.69 2.63 -0.42 2.65 
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Table 19: Means of Technology Items about Electronic Prescribing Based on Respondents Current E-Prescribing Status 
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, No 
Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Technology 1.68 1.73 0.96 1.65 0.93 2.22 0.90 1.94 0.27 2.04 1.27 1.90 
Access of e-prescribing systems 
from different locations 
1.85 2.50 1.48 2.16 1.29 2.37 1.41 2.67 0.67 2.54 1.57 2.49 
Number of pharmacies 
participating in e-prescribing 
2.32 2.23 1.24 2.60 1.32 2.68 1.22 2.37 0.63 2.44 1.79 2.42 
Availability of Electronic Medical 
Records/Electronic Health Records 
that incorporate e-prescribing 
2.31 2.20 1.52 2.12 1.56 2.50 1.68 2.52 0.82 2.56 1.92 2.37 
Number of payers connected to e-
prescribing technology 
1.53 2.12 0.48 2.52 1.00 2.70 1.17 2.28 0.24 2.31 1.20 2.28 
Security of electronically sent 
prescriptions 
2.13 2.32 1.68 2.36 1.21 3.15 0.84 2.65 0.27 2.93 1.59 2.62 
Effect on overall prescribing error 
rates due to e-prescribing  
1.56 2.34 1.28 1.77 1.15 2.55 1.33 2.36 0.86 2.33 1.39 2.33 
Quality of currently available e-
prescribing software 
1.39 2.37 -0.08 2.63 0.62 2.66 0.35 2.42 -0.22 2.34 0.87 2.49 
The need for high speed Internet 
for the transmission of an 
electronic prescription 
0.94 2.10 0.88 1.92 0.26 2.49 0.16 2.13 -0.14 1.73 0.62 2.12 
Availability of software that 
supports the current workflow in 
my practice 
1.10 2.27 0.12 2.13 0.00 2.70 -0.48 2.52 -0.75 2.61 0.54 2.47 
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Table 20: Means of Features Items about Electronic Prescribing Based on Respondents Current E-Prescribing Status 
 
 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Features 2.39 1.74 1.70 1.48 2.59 1.73 2.61 1.67 1.99 1.91 2.35 1.75 
Availability of feedback from 
pharmacy regarding patient 
compliance during refills 
1.62 2.53 0.88 2.19 2.03 2.56 2.32 2.28 1.78 2.59 1.74 2.50 
Availability of prescription 
receipt confirmation from the 
pharmacy 
1.77 2.46 1.12 2.37 2.15 2.45 2.30 2.39 1.55 2.28 1.82 2.43 
Availability of comprehensive 
formulary information 
2.49 2.27 2.00 1.96 3.03 1.64 2.81 1.99 2.41 2.05 2.54 2.14 
Availability of safety drug 
alerts during e-prescribing 
2.27 2.34 1.12 2.28 2.88 2.00 2.78 2.04 2.35 2.17 2.34 2.27 
Availability of comprehensive 
patient insurance eligibility 
information 
2.11 2.30 1.52 1.76 2.56 2.03 2.37 2.07 1.84 2.26 2.12 2.21 
Availability of refill function in 
the e-prescribing system 
3.33 1.89 2.92 2.04 3.26 1.76 3.14 1.80 2.33 2.14 3.15 1.93 
Availability of patient medical 
history in the electronic 
prescribing system 
3.12 2.07 3.32 2.51 2.20 2.40 2.57 1.95 1.63 2.76 2.72 2.26 
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Table 21: Means of External Influence Items about Electronic Prescribing Based on Respondents Current E-Prescribing 
Status 
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
External Influence 0.30 1.56 0.22 1.44 0.17 2.39 -0.10 1.74 -0.64 1.78 0.11 1.72 
Government 
education/awareness initiatives 
to promote e-prescribing 
0.44 2.17 0.84 1.89 0.24 2.52 0.30 2.30 -0.20 1.97 0.37 2.18 
E-prescribing software vendors 
promotion of e-prescribing 0.15 1.84 0.16 1.60 0.21 2.53 0.11 2.02 -0.47 1.88 0.67 1.93 
Medicare’s monetary 
incentives for e-prescribing 
adoption 
1.10 2.45 1.12 2.64 0.88 2.99 0.75 2.40 -0.14 2.63 0.87 2.55 
Medicare’s monetary 
disincentives for e-prescribing 
adoption 
0.12 2.45 0.24 2.73 -0.15 3.27 -0.05 2.70 -1.12 2.45 -0.08 2.60 
Ongoing policy changes 
related to e-prescribing 0.31 2.30 -0.32 2.48 -0.26 2.80 -0.71 2.65 -1.24 2.49 -0.13 2.49 
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Table 21 (cont): Means of External Influence Items about Electronic Prescribing Based on Respondents Current E-
Prescribing Status  
 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
External Influence 0.30 1.56 0.22 1.44 0.17 2.39 -0.10 1.74 -0.64 1.78 0.11 1.72 
Availability of national 
standards related to e-
prescribing 
0.45 2.39 -0.68 2.50 0.09 2.84 -0.71 2.56 -1.04 2.69 -0.01 2.56 
Availability of appropriate 
vendors for my practice 0.13 2.08 0.48 1.69 0.38 2.69 -0.17 2.28 -0.45 2.10 0.05 2.16 
The lack of adoption of e-
prescribing by other physicians -0.28 1.48 -0.12 1.39 0.00 2.45 -0.27 1.60 -0.65 1.53 -0.29 1.60 
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Table 22: Means of Patients Items about Electronic Prescribing Based on Respondents Current E-Prescribing Status 
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Patients 1.63 1.97 0.74 2.34 1.11 2.09 0.86 1.87 0.35 2.09 1.25 2.05 
Effect of e-prescribing on the 
physician-patient conversation 
during the visit 
1.33 2.29 -0.04 2.76 1.00 2.32 0.41 2.35 0.24 2.27 0.94 2.37 
Effect of patients’ perceptions 
on my use of e-prescribing 
technology 
1.78 2.24 0.72 2.78 1.44 2.16 1.06 1.87 0.45 2.21 1.40 2.26 
Effect of e-prescribing on 
patients’ likelihood to pick up 
their medication from the 
pharmacy 
1.38 2.09 1.04 2.28 1.23 2.61 0.98 1.90 0.49 2.10 1.17 2.13 
Ability to maintain patient 
confidentiality when e-
prescribing 
2.03 2.34 1.24 2.65 0.76 2.70 0.98 2.52 0.24 2.67 1.48 2.54 
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Table 23: Means of Post-Implementation Items about Electronic Prescribing Based on Respondents Current E-Prescribing 
Status 
 
 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Post-Implementation 1.57 2.13 0.73 1.78 0.68 2.34 0.59 2.06 -0.03 2.24 1.09 2.21 
Comfort level with writing 
electronic prescriptions 
2.25 2.37 1.96 2.17 0.62 2.97 0.62 2.55 0.43 2.50 1.61 2.57 
Time required for an electronic 
prescription to reach the 
pharmacy 
1.86 2.60 1.28 2.95 1.74 2.71 1.41 2.35 0.57 2.63 1.58 2.62 
Effect on productivity after e-
prescribing implementation 
1.14 2.49 0.52 2.10 0.41 2.99 0.41 2.75 -0.14 2.97 0.77 2.65 
Time taken to complete an 
electronic prescription 1.03 2.74 -0.84 3.07 -0.03 3.05 -0.08 2.73 -1.00 2.55 0.40 2.86 
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Table 24: Means of Cost Items about Electronic Prescribing Based on Respondents Current E-Prescribing Status 
 
 
  
TTM Stages Maintenance Action Preparation Contemplation 
During-
Contemplation 
 
Factors
a
 
Group 1 
Adopted  
> 6 months 
Group 2 
Adopted  
< 6 months 
Group 3 
In process 
< 1 month 
Group 4 
In Process 
Next 6 months 
Group 5 
Considered, 
No Intention 
Total 
 N = 232 N = 25 N = 34 N = 63  N = 51 N = 405 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Cost -0.61 2.22 -1.09 2.04 -0.69 3.00 -1.72 2.36 -1.90 2.57 -0.98 2.40 
Financial cost of 
updating/upgrading the e-
prescribing system 
-0.69 2.42 -1.28 1.92 -0.94 3.21 -1.78 2.49 -2.06 2.75 -1.09 2.57 
Initial cost of implementation -0.78 2.47 -1.00 2.53 -1.15 3.29 -2.04 2.30 -2.10 2.74 -1.19 2.61 
Return on investment related to 
e-prescribing 
-0.35 2.44 -1.00 2.10 0.03 3.02 -1.33 2.81 -1.55 2.68 -0.67 2.61 
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